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“Three grand essentials to happiness in this life are something to do, 
something to love, and something to hope for.” 
 
Joseph Addison (1672–1719) 
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2 ABBREVIATIONS AND SYNONYMS 
Reduction mammaplasty Breast reduction, reduction mammoplasty 
Breast hypertrophy  Macromastia 
Intertrigo   Rash in body folds (in this case under the breast) 
Bottoming-out Pseudoptosis, descend of inferior breast and upward 
rotation of the nipple 
Ptosis Descend of the nipple (and the breast) 
HRQoL Health Related Quality of Life 
Health burden Health deficit, loss of quality of life 
QALY(s)   Quality-adjusted life year(s) 
Cost-utility analysis Analysis of cost per QALY: in medicine the term is 
often used interchangeably with cost-effectiveness 
SF-36    Short Form-36 quality of life questionnaire 
SF-6D    Single index score of SF-36 
PCS    Physical summary score of SF-36 
MCS     Mental summary score of SF-36 
15D    15D quality of life questionnaire 
15D score   Single index score of 15D 
FBAS    Finnish Breast-Associated Symptoms questionnaire 
FPQ    Finnish Pain Questionnaire 
RBDI Raitasalo’s modification of the Beck Depression 
Inventory (BDI) 
 BRSQ    Breast-Related Symptoms Questionnaire 
RCT(s)   Randomised controlled trial(s) 
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3 ABSTRACT 
Background 
 
Symptomatic hypertrophic breasts cause a health burden with physical and 
psychosocial morbidity. The value of reduction mammaplasty in the treatment of 
symptomatic breast hypertrophy has been consistently reported by patients and has 
been well recognised by plastic surgeons for a long time. However, the scientific 
evidence of the effects of reduction mammaplasty has been weak or lacking. 
During the design of this study most of the previous studies were retrospective 
and the few prospective studies had methodological limitations. Therefore, an 
obvious need for prospective randomised studies was present. Nevertheless, 
practical and ethical considerations seemed to make this study design impossible, 
because the waiting time for the operation was several years. The legislation and 
subsequent introduction of the uniform criteria for access to non-emergency 
treatment in Finland removed these obstacles, as all patients received their 
treatment within a reasonable time. As a result, a randomised controlled trial with a 
six-month follow-up time was designed and conducted. In addition, a follow-up 
study with two to five years’ follow-up was also carried out later. The effects of 
reduction mammaplasty on the patients’ breast-related symptoms, psychological 
symptoms, pain and quality of life was assessed. In addition, factors affecting the 
outcome were investigated. 
 
Patients and Methods 
 
This study was carried out in the Hospital District of Helsinki and Uusimaa, 
Finland. Eighty-two out of the approximately 300 patients on the waiting list in 
2004 agreed to participate in the study. Patients were randomised either to be 
operated (40 patients) on or to be followed up (42 patients). The follow-up time for 
both groups was six months. The patients were operated on by plastic surgeons or 
trainees at the Department of Plastic Surgery at Helsinki University Central 
Hospital or at the Department of Surgery at Hyvinkää Hospital. The patients 
completed five questionnaires: the SF-36 and the 15D quality of life 
questionnaires, the Finnish Breast-Associated Symptoms questionnaire (FBAS), a 
mood questionnaire (Raitasalo’s modification of the short form of the Beck 
Depression Inventory, RBDI), and a pain questionnaire (The Finnish Pain 
Questionnaire, FPQ). Sixty-two out of the original 82 patients agreed to participate 
in the prospective follow-up study. In this study, patients completed the 15D 
quality of life questionnaire, the Finnish Breast-Associated Symptoms 
questionnaire, and the RBDI mood questionnaire. 
 
Results 
 
After six months’ follow-up, patients who had undergone reduction mammaplasty 
had a significantly better quality of life, fewer breast-associated symptoms and less 
pain, and they were less depressed or anxious when compared to patients who had 
not undergone surgery. The change in quality of life was more than two times the 
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minimal clinically important difference. The patients’ preoperative quality of life 
was significantly inferior when compared to the age-standardised general 
population. This health burden was removed with reduction mammaplasty. The 
health loss related to symptomatic breast hypertrophy was comparable to that of 
patients with major joint arthrosis. In terms of change in quality of life, the 
intervention effect of reduction mammaplasty was comparable to that of hip joint 
replacement and more pronounced than that of knee joint replacement surgery. The 
outcome of reduction mammaplasty was affected more by preoperative 
psychosocial factors than by changes in breast dimensions. The effects of reduction 
mammaplasty remained stable at two to five years’ follow-up. 
 
Conclusions 
 
In terms of quality of life, symptomatic breast hypertrophy causes a considerable 
health loss comparable to that of major joint arthrosis. Patients who undergo 
surgery have fewer breast-associated symptoms and less pain, and they are less 
depressed or anxious and have an improved quality of life. The intervention effect 
is comparable to that of major joint replacement surgery, and it remains stable at 
two to five years’ follow-up. The outcome of reduction mammaplasty is affected 
by preoperative psychosocial factors. 
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4 INTRODUCTION 
The value of reduction mammaplasty in the treatment of symptomatic breast 
hypertrophy has been consistently reported by patients and has been well 
recognised by plastic surgeons for a long time. Symptomatic hypertrophic breasts 
cause a health burden with physical and psychosocial morbidity, affecting the 
patients’ quality of life. This condition can be treated by reducing the weight of the 
heavy breasts. The physical symptoms reported by patients include headache, 
upper and lower back pain, shoulder pain, brassiere strap grooving, and rashes 
under the breasts. The psychosocial consequences are depression, anxiety, low self-
esteem and dissatisfaction with body image, as well as difficulties in intimate 
relations and in participating in sports or social activities due to embarrassment. 
However, the scientific evidence of the effects of reduction mammaplasty has been 
weak or lacking. A meta-analysis reviewing the medical literature from 1985 to 
1999 failed to recognise any prospective randomised studies (Chadbourne et al. 
2001). Most of the studies were retrospective and the few prospective studies had 
methodological limitations. The paucity of solid scientific evidence raised the 
obvious need for prospective randomised studies (Iwuagwu et al. 2004), but 
practical and ethical considerations were thought to make this kind of study design 
impossible (Collins et al. 2002, Iwuagwu et al. 2004). 
Patients’ satisfaction with reduction mammaplasty has been previously studied 
at Helsinki University Central Hospital (Tykkä et al. 2001). In the present study the 
primary aim was to assess the effects of reduction mammaplasty. A comparison of 
the health burden (loss of quality of life) of symptomatic breast hypertrophy (in 
terms of general quality of life) with the general population and other surgical 
patient populations was carried out. This is required in order to identify and 
establish the value of reduction mammaplasty with respect to other surgical 
treatments. A search for factors affecting the outcome of reduction mammaplasty 
was also undertaken. Finally, an analysis of two to five years’ (medium-term) 
follow-up data of reduction mammaplasty was carried out. 
At the time when the present study was being designed and conducted, the 
formulation of the uniform criteria for access to non-emergency treatment in 
Finland was on the way. The act eventually came into force on 1 March 2005 
(Finnish Ministry of Social Affairs and Health 2005), when this study was halfway 
through and all patients received their treatment within a reasonable time whether 
they participated in the study or not. Therefore, it was possible to design a 
randomised clinical trial with a six-month follow-up for the assessment of the 
short-term results. In order to achieve a comprehensive picture of the results, five 
questionnaires measuring different aspects of the effects of reduction mammaplasty 
were applied. We used two quality of life instruments complementing each other, 
as recommended in the literature (Hawthorne et al. 2001). As a condition-specific 
element, breast-related symptoms were evaluated. Pain is a central symptom and 
was therefore approached separately. The psychological aspects of reduction 
mammaplasty are another important area of consideration and they were also 
assessed separately. The medium-term results in terms of quality of life as well as 
breast-related and psychological symptoms were collected from the same 
prospective study population by post at two to five years’ follow-up. 
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5 REVIEW OF THE LITERATURE 
5.1 Definition of symptomatic breast hypertrophy and patient 
selection for surgery 
Symptomatic breast hypertrophy has been described as chronic pain symptoms in 
at least three certain anatomic areas (head, neck, shoulder, bra groove, back or 
breast) in the upper body (Gonzalez et al. 1993b). Breast hypertrophy itself can be 
defined as the top 10th percentile in breast size of the female population (in the U.S. 
at least 750 cc or bra cup D) (Kerrigan et al. 2002). Definitions of cosmetic and 
reconstructive surgery were adopted by the American Medical Association in 1989 
(American Society of Plastic Surgeons 2002). According to these definitions 
“reconstructive surgery is performed on abnormal structures of the body, caused by 
congenital defects, developmental abnormalities, trauma, infection, tumours or 
disease. It is generally performed to improve function, but may also be done to 
approximate a normal appearance.” In contrast “cosmetic surgery is performed to 
reshape normal structures of the body in order to improve the patient’s appearance 
and self-esteem.” The guidelines of reconstructive plastic surgery can also be 
applied to symptomatic hypertrophic breasts. Recently symptomatic breast 
hypertrophy has been stated to include a large variety of symptoms (Sigurdson et 
al. 2007a, Sigurdson et al. 2007b, Klassen et al. 2009, Pusic et al. 2009). 
Instruments specifically designed for symptomatic breast hypertrophy measure 
physical, psychosocial and sexual well-being. 
Attempts at creating predictive objective models for successful surgery in breast 
hypertrophy (based on weight, height, body area or reduction specimen weight) 
have failed (Schnur et al. 1991, Miller et al. 1995, Seitchik 1995). On the contrary, 
the improvement in symptoms after surgery is independent of bra cup size, the 
weight of resection, height, weight, or body mass index (Gonzalez et al. 1993b, 
Collins et al. 2002). Patients with smaller resection weights per breast have an 
equal improvement in breast-related symptoms as those with greater resections 
(Spector and Karp 2007, Thoma et al. 2007). Only an increasing number of co-
morbid conditions have had a negative impact on the results (Collins et al. 2002). 
Previous studies have also noted a link between postoperative patient 
dissatisfaction and patient anxiety and/or depression, as well as the quality of the 
preoperative information, and patient-surgeon relations (Cerovac et al. 2005, 
Chahraoui et al. 2006). 
Strömbeck and Malm introduced a priority grouping model for breast 
hypertrophy (Strombeck and Malm 1986). However, the model was more or less 
based on subjective, though clinically practical factors. The model was 
subsequently evaluated and it was concluded that it is an useful tool for selecting 
and priority grouping patients (Blomqvist 1996). It was certainly demonstrated that 
the tool worked in the way it was designed and it was widely used. However, the 
design of the system was not fully justified, but further modified on a somewhat 
subjective basis. The statement that this system is a useful tool for selecting 
patients and classifying priorities rouses up disagreement, because it has not been 
demonstrated that the outcome gain is related to the system itself. 
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Similarly, a height to sternal-notch-to-nipple ratio of less than five has been 
proposed as an “objective” discriminating criterion for reduction mammaplasty 
(Nicoletti et al. 2009). This ratio was obtained and applied into practice from 
retrospective reduction mammaplasty data and did not solve the problem of 
selecting patients for reduction mammaplasty. 
At the moment the medical need for breast reduction surgery is still better 
defined by self-reports of symptoms rather than by the degree of breast 
hypertrophy present or the amount of breast removed (American Society of Plastic 
Surgeons 2002, Kerrigan et al. 2002). Recently designed instruments specifically 
for symptomatic breast hypertrophy may introduce new aspects in selecting 
patients. The content of these instruments have been derived from qualitative 
patient interviews (Sigurdson et al. 2007a, Sigurdson et al. 2007b, Klassen et al. 
2009, Pusic et al. 2009). These strictly validated instruments may later be 
appropriate for patient selection by comparing the symptom levels found to those 
among the general population. 
5.2 Outcomes in reduction mammaplasty 
5.2.1 Assessing outcomes in reduction mammaplasty 
An ideal outcome measure should be designed and developed specifically for a 
patient subgroup (Pusic et al. 2007a). It should be reliable (able to demonstrate 
consistent and reproducible scores), valid (able to measure what it is intended to 
measure), and responsive (sensitive to change). 
In breast reduction surgery, symptom-based questionnaires have been 
traditionally used. During the last ten years, quality of life measurement has gained 
more interest, in addition to issues related to body image and self-esteem as well as 
the evaluation of psychosocial symptoms. Numerous outcome instruments have 
been used to assess aesthetic and reconstructive breast surgery (Ching et al. 2003, 
Pusic et al. 2007a). However, validated condition-specific instruments for 
symptomatic breast hypertrophy have been lacking (Pusic et al. 2007a). Until 
recently, only one breast reduction surgery instrument (Breast-Related Symptoms 
Questionnaire, BRSQ) (Kerrigan et al. 2001, Collins et al. 2002), has demonstrated 
acceptable development and validation. However, it has some content validity 
limitations. Therefore other instruments, such as quality of life and body image 
questionnaires have been used to complement the BRSQ outcome measure. For 
that reason, new outcome instruments containing items and domains covering 
physical, psychosocial and sexual well-being as well as patient satisfaction with the 
breast, outcome and care have been developed and validated (Sigurdson et al. 
2007a, Sigurdson et al. 2007b, Klassen et al. 2009, Pusic et al. 2009). These 
instruments have items collected qualitatively through patient interviews therefore 
representing the true perspective of symptomatic breast hypertrophy. However, 
clinical studies applying these new instruments are yet to be conducted. 
When choosing an outcome measure, a selection between or a combination of 
generic and condition-specific outcome measure should be made (Pusic et al. , 
Cano et al. 2009). A generic (quality of life) outcome measure has the advantage of 
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providing a tool for comparing different conditions and treatments with others or 
the general population. Nevertheless, it may not offer sufficient content validity or 
responsiveness to assess the effects of an intervention. On the other hand, a 
condition- specific outcome measure covers the area of interest studied more 
precisely and is therefore supposed to have better content validity and 
responsiveness. A recommendation of complementing a generic quality of life 
outcome measure with another one has been presented (Hawthorne et al. 2001). 
Overall, measuring general quality of life includes physical, social and mental 
well-being. The assessment of condition-specific quality of life adds important 
aspects or dimensions. In reduction mammaplasty, for instance, this means the 
evaluation of satisfaction with breast shape, size and symmetry, in addition to 
scars, the nipple-areola complex position and sensitivity among other things. These 
items and their importance are derived from patients, health professionals and the 
literature. Further formation of the outcome instrument is done by rigorous 
validation work as described recently in breast reduction surgery (Pusic et al. 
2007b, Sigurdson et al. 2007a). The so-called Patient-Reported Outcome Measures 
(PROMs) are essential in assessing quality of life and patient satisfaction in surgery 
(Chow et al. 2009, Pusic et al. 2010). 
5.2.2 Systematic reviews 
A systematic review and meta-analysis of the published studies from 1985 to 1999 
concluded improved clinical outcomes after reduction mammaplasty (Chadbourne 
et al. 2001). Twenty-nine out of the potential 131 studies met the eligibility criteria 
for meta-analysis. Most of the investigations were retrospective in design. A few 
prospective studies, but no prospective randomised controlled trials (RCTs) were 
found. The symptoms found to be improved were shoulder pain, shoulder 
(brassiere strap) grooving, upper and lower back pain, neck pain, rashes under the 
breasts, breast pain, headache, and pain or numbness of the hands. Physical 
functioning in health-related quality of life was also improved. However, the 
changes in psychological functioning were not statistically significant. A study 
reviewing the literature from 1966 to 1997 found a consistent improvement in 
physical symptoms and quality of life and a high degree of patient satisfaction 
(Jones and Bain 2001). Some improvement in body image and psychological well-
being was also noted. However, the authors concluded that the criteria for meta-
analysis were not fullfilled. In another review comparing outcome data for five 
classical and commonly used reduction mammaplasty techniques, a high rate of 
both physical and psychological improvement was reported (Daane and Rockwell 
1999). 
5.2.3 Prospective studies 
After an era of retrospective studies mostly describing different techniques in 
reduction mammaplasty, a significant number of prospective studies have been 
published during the last 20 years (Hollyman et al. 1986, Gonzalez et al. 1993b, 
Hughes and Mahoney 1993, Cole et al. 1994, Klassen et al. 1996a, Klassen et al. 
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1996b, Shakespeare and Cole 1997, Starley et al. 1998, Giovanoli et al. 1999, 
Shakespeare and Postle 1999, Souza Faria et al. 1999, Behmand et al. 2000, 
Blomqvist et al. 2000, Chao et al. 2002, Collins et al. 2002, Harbo et al. 2003, Sood 
et al. 2003, Blomqvist and Brandberg 2004, Freire et al. 2004, Miller et al. 2005, 
Chahraoui et al. 2006, O'Blenes et al. 2006, Spector et al. 2006, Borkenhagen et al. 
2007, Moskovitz et al. 2007, Spector and Karp 2007, Thoma et al. 2007, Eggert et 
al. 2009, Mello et al. 2009, Rogliani et al. 2009, Adham et al. 2010, Tykkä et al. 
2010). However, some methodological drawbacks have affected the quality of 
these prospective outcome studies. When criteria for high-quality outcome 
assessment are applied – as regards validated outcome instruments or measures, 
adequate population size (minimum of 30 patients) as well as acceptable follow-up 
time (min. 6 months) and rate (about 3/4 or more) – a substantial number of studies 
still remain to be considered (Shakespeare and Cole 1997, Behmand et al. 2000, 
Blomqvist et al. 2000, Chao et al. 2002, Collins et al. 2002, Blomqvist and 
Brandberg 2004, Freire et al. 2004, Miller et al. 2005, O'Blenes et al. 2006, 
Borkenhagen et al. 2007, Thoma et al. 2007, Rogliani et al. 2009, Tykkä et al. 
2010) (Table 1). In these studies improvement has been detected in quality of life, 
breast-associated symptoms, pain, muscle strength and posture, lumbar spine 
disability, psychological distress, self-esteem and body image as well as pulmonary 
function. 
Rogliani et al. (2009) assessed 116 patients after 12 months. Four patients were 
lost to follow-up. A quality of life (SF-36) questionnaire, a condition-specific 
Symptom Inventory Questionnaire (SIQ), and a Body Dysmorphic Disorder 
Examination Self-Report (BDDE-SR23) questionnaire were used to measure 
outcome. All showed significant improvement. 
Thoma et al. (2007) included 52 consecutive patients in their study. Their 
follow-up time was 12 months. At this point, however 19 patients (37%) were lost 
to follow-up. At six months follow-up, eight (15%) patients were lost. The 
instruments used were three quality of life questionnaires (Health Utilities Index 
Mark 2; HUI2, Health Utilities Index Mark 3; HUI3, and Short Form 36; SF-36), a 
condition-specific Breast Related Symptom Questionnaire (BRSQ) to measure 
breast-related symptoms, and the Multidimensional Body Self Relations 
Questionnaire (MBSRQ) to assess body image. At six months’ follow-up, there 
was a significant reduction in pain and breast-related symptoms, improvement in 
the physical and mental summary scores of SF-36, and improvement in body 
image. 
Behmand et al. (2000) had 69 patients followed-up for nine months. As outcome 
instruments they used the Short Form 36 (SF-36) to assess quality of life and the 
Brief Symptom Inventory (BSI) to assess psychological symptoms. Preoperatively, 
they found inferior quality of life and more psychological symptoms among the 
patients when compared to the general population. Postoperatively there was a 
statistically significant improvement in all measures. 
Miller et al. (2005) enrolled 56 patients to their prospective study. The Short 
Form 36 (SF-36) quality of life questionnaire, the Symptoms Inventory 
Questionnaire (SIQ) for breast-related symptoms, and the Rosenberg Self-Esteem 
Scale (RSES) were applied for outcome analysis. All showed significant 
improvement at six months’ follow-up. In addition, several quality of life scores 
were inferior to those of the general population preoperatively, and these were 
normalised postoperatively. 
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Chao et al. (2002) focused on lumbar spine disability (North American Spine 
Society Lumbar Spine Outcome Assessment Instrument), muscle strength 
(Kendall’s muscle grading scale), posture (Harrison’s objective clinical 
measurements) and pain (Visual Analogue Scale) when assessing women before 
reduction mammaplasty and at six months’ follow-up. Fifty-five patients showed 
significant improvement in all measures. Although not using a specific instrument 
measuring breast reduction benefits, this study introduced an interesting viewpoint. 
Shakespeare and Cole (1997) enrolled 110 patients to their prospective study 
and received follow-up data from 84 (76%) patients at six months. The Short Form 
36 (SF-36) quality of life questionnaire and Rosenberg Self-Esteem Scale (RSES) 
were used as outcome measures. Both showed significant improvement from the 
preoperative to the postoperative state. The preoperative quality of life values 
inferior to those of the general population were normalised postoperatively. 
Blomqvist et al. (2000) assessed 38 (78%) out of 49 patients at 12 months’ 
follow-up. In addition to the Short Form 36 (SF-36) quality of life questionnaire, 
they assessed pain and discomfort symptoms. Quality of life and pain improved 
significantly after the operation. At three years’ follow-up with the same 
population, the results were found to have remained stable (Blomqvist and 
Brandberg 2004). 
Freire et al. (2004) evaluated quality of life with the Short Form 36 (SF-36) 
questionnaire preoperatively in 44 patients. Forty (91%) patients attended the six-
month follow-up. However, smokers as well as those with chronic diseases, regular 
medication or body mass index over 30, or those who had breast-fed recently, were 
excluded from study. Nevertheless, the authors found a significant improvement in 
all areas of quality of life. 
Borkenhagen et al. (2007) followed 40 consecutive patients for 6 months. 
Thirty-four patients (85%) completed the study. Several German standardised 
questionnaires were used to assess health-related quality of life (WHO Quality of 
Life Assessment, WHOQOL-BREF, 26 items), physical symptoms and complaints 
(Gieβener Beschwerdebogen; GBB, 24-item scale version), psychological well-
being (Berliner Stimmungsfragebogen; BSE, 6-scale version per 5 items), and life 
or global satisfaction (Lebenzufriedenheitsinventar; LZI, 15 items, and Anamnestic 
Comparative Self Assessment, ACSA, 1 item). A significant improvement was 
detected in psychological well-being and muscle complaints. However, physical 
well-being improved but the difference was not statistically significant. Increased 
euphoria was detected at six months’ follow-up whereas other mood or affect 
characteristics improved but were not statistically significant. 
In the original study by Collins et al. (2002) a total of 243 patients undergoing 
reduction mammaplasty were included. A set of standardised and validated 
instruments was used to assess outcome: the Short Form 36 (SF-36) and the 
European Quality of Life (EuroQol) for quality of life, the Multidimensional Body 
Self Relations Questionnaire (MBSRQ) for body image, Breast-Related Symptoms 
Questionnaire (BRSQ) for specific breast symptoms, and McGill Pain 
Questionnaire (MPQ) for pain. Control subjects, with hypertrophy controls (n = 88) 
and normal controls (n = 96), were also included in the study. At follow-up (mean 
8.2, range 5.6–20.9 months) 179 patients (74%) were assessed. All measures, 
except for the fitness orientation of MBSRQ, showed statistically significant 
change from the preoperative to the postoperative situation. Postoperatively, the 
patients still reported higher pain levels than normal controls. Subjects with more 
co-morbidities gained less postoperative improvement. 
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O’Blenes et al. (2006) prospectively followed 68 patients and collected 
postoperative information at six and 21.5 months. The surveys were mailed. 
Breast-related symptoms, quality of life (SF-36) and the Rosenberg self-esteem 
questionnaire were used as outcome measures. Fifty-seven (84%) patients returned 
the mid-term follow-up surveys. The alleviation in breast-related symptoms and 
restoration of self-esteem remained stable and significant at both follow-up points. 
Quality of life was also significantly improved, except for the role emotional 
(limitations in usual role activities due to emotional problems) and mental health 
summary scores. The results also indicated that reduction mammaplasty provides 
rather physical than emotional improvement. However, some decrease in quality of 
life from the short-term to the long-term follow-up was noted. This was explained 
by a possible euphoria effect shortly after surgery. 
As part of a larger prospective trial assessing health-related quality of life, 
Tykkä et al. (2010) followed 89 patients for six months. Eighty patients (90%) 
returned the six-month questionnaire. A significant improvement in overall quality 
of life (15D index score) was detected after reduction mammaplasty. Discomfort 
and symptoms showed the most improvement out of the dimensions of the 15D 
questionnaire. 
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5.2.4 Randomised studies 
A prospective randomised clinical trial (RCT) provides the strongest scientific 
evidence of a medical intervention. Ideally, it is blinded, preferably double-blinded 
– i.e., neither the patient nor the observer is aware of the treatment allocation. 
However, in visible plastic surgery, such as with reduction mammaplasty, blinding 
is impossible. Two randomised trials have been conducted during the recent years 
(Iwuagwu et al. 2005, Iwuagwu et al. 2006c, Iwuagwu et al. 2006d, Iwuagwu et al. 
2006e, Freire et al. 2007, Neto et al. 2008). In these studies breast reduction has 
had a significantly positive impact on quality of life (Iwuagwu et al. 2006e), 
functional capacity and pain (Freire et al. 2007, Neto et al. 2008), depression and 
anxiety (Iwuagwu et al. 2006d, Iwuagwu et al. 2006e), self-esteem (Neto et al. 
2008), and psychosocial aspects (Iwuagwu et al. 2006e). However, changes in lung 
function are less clear (Iwuagwu et al. 2006c), although patients with a greater 
resection seem to gain more from the procedure in terms of work of their breathing. 
While patients with macromastia seem to have an increased tendency to carpal 
tunnel syndrome (Iwuagwu et al. 2006a), an effect of breast reduction on nerve 
conduction to the upper limbs has not been noted (Iwuagwu et al. 2005). 
In their prospective randomised clinical trial, Iwuagwu et al. (2006c, 2006d, 
2006e and 2005) randomly allocated the patients either to have reduction 
mammaplasty within six weeks of the first examination or a delayed operation 
within six months of recruitment. The outcome measures included quality of life, 
psychological and psychosocial factors, lung function tests and upper-limb nerve 
conduction tests. The trial consisted of 73 patients, 36 of whom were assigned to 
have early and 37 delayed surgery. In two of the studies assessing quality of life, as 
well as psychological and psychosocial factors, all patients completed the study 
(Iwuagwu et al. 2006d, Iwuagwu et al. 2006e). In the study assessing lung function, 
eight patients were lost to follow-up, four in both groups (Iwuagwu et al. 2006c). 
The recruitment period in the study assessing nerve conduction of the upper limbs 
was only nine months in comparison to the 20 months of the other three studies, 
and therefore only 31 patients (16 to early, and 15 delayed intervention) were 
randomised (Iwuagwu et al. 2005). The follow-up time was three to four months. 
In their studies Iwuagwu et al. found that reduction mammaplasty significantly 
improved quality of life and emotional stability, and reduced the amount of 
depression and anxiety. No statistically significant effect was noted on lung 
function or nerve conduction of the upper limbs. 
In the second RCT, 100 patients were randomly allocated to have immediate 
surgery (50 patients) or follow-up (Freire et al. 2007, Neto et al. 2008). The 
recruitment period coincided with that of the RCT of Iwuagwu et al. The follow-up 
time was six months. The outcome measures included functional capacity, pain and 
self-esteem. Freire et al. (2007) and Neto et al. (2008) found that reduction 
mammaplasty significantly improved functional capacity and self-esteem, and 
relieved pain in the lower back, shoulders and neck. However, smokers, patients 
with chronic diseases or regular medication as well as those with a body mass 
index over 30 or who had breast-fed recently were excluded from the study. 
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5.2.5 Medium and long-term results 
Only a few medium-term prospective follow-up studies of reduction mammaplasty 
have been published. In a qualitative study the effects of breast reduction seem to 
remain stable at two years’ follow-up (Shakespeare and Postle 1999). In two 
studies utilising standardised and validated instruments the effects of reduction 
mammaplasty stays stable and clinically substantial at two to three years’ follow-
up (Blomqvist and Brandberg 2004, O'Blenes et al. 2006). During the first months, 
a “honeymoon effect” can be detected, with stabilised results still comparable to 
population norms occurring later on (Blomqvist and Brandberg 2004, O'Blenes et 
al. 2006). Blomqvist et al. (2004) reported a small non-significant increase in 
patient-reported pain, especially headaches, from one to three years’ follow-up. 
They concluded these changes to be connected to other factors than breast 
problems. However, a similar trend was also noted in patient-reported problems 
related to breast size and weight. Prospective long-term studies cannot be found in 
the literature. 
5.2.6 Quality-adjusted life years and cost-utility of reduction 
mammaplasty 
The gain in quality-adjusted life after reduction mammaplasty is approximately 
five years (Thoma et al. 2007). In other words, after breast reduction patients get to 
live in perfect health for several extra years, when compared to the alternative of 
dying immediately. This gain is cumulative during the additional life expectancy 
(approximately 30–40 years), but it gives a concrete example of the kind of impact 
an effective and early intervention has on quality of life. Others have suggested that 
conservative treatment attempts quickly exceed the costs of surgical treatment of 
symptomatic breast hypertrophy (Scholz et al. 2008). 
Two studies (Taylor et al. 2004, Tykkä et al. 2010) have assessed the cost per 
quality-adjusted years (QALYs). In the most recent study (Tykkä et al. 2010), the 
QALYs gained after reduction mammaplasty were 0.930. With a 5% discount rate, 
the QALYs gained were 0.377. With a mean hospital cost of €3,383 of reduction 
mammaplasty, the mean cost per QALY was €3,638. With a 5% discount rate the 
cost per QALY was €8,973. In the other study (Taylor et al. 2004), the cost per 
QALY for breast reduction was approximately € 6,000–7,200. However, the 
Health-Related QoL data was obtained from a Swedish population, while the costs 
were derived from a British population. 
In comparison to other interventions for other medical conditions, the cost per 
QALY obtained by breast reduction surgery is reasonable and indicates its cost-
effectiveness. In Finnish studies using the 15D quality of life questionnaire, the 
cost per QALY has been found to be comparable to cervical or lumbar spine 
operations (anterior decompression of cervical spine [€2,770], or lumbar spine 
decompression to treat herniated disc or spondylosis [€1,740]) (Räsänen et al. 
2006b), for hip arthroplasty (€6,710) or knee arthroplasty (€13,995) (Räsänen et al. 
2007), cataract surgery (€7,947) (Räsänen et al. 2006a), or superficial venous 
surgery (€3,248) (Eskelinen et al. 2009). 
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5.2.7 Long-term sequelae of reduction mammaplasty 
In Finland it has traditionally been recommended to women that they to have 
children before reduction mammaplasty to ensure successful breastfeeding. 
However, a recent review article found that women who have had reduction 
mammaplasty have an equal breastfeeding capacity when compared to women in 
the general population (Thibaudeau et al. 2010). Technically, it is important to 
preserve connections from the nipple-areola complex to a sufficient number of 
ducts and lobules. The majority of the reasons for breastfeeding difficulties are 
related psychosocial factors. Therefore, it is important to provide accurate 
information and encourage women to attempt breastfeeding even after reduction 
mammaplasty. 
Advances in understanding the innervation anatomy have resulted in better 
understanding of how different techniques affect the sensation of the nipple-areola 
complex (Kuzbari and Schlenz 2007). Lateral, medial, inferior and central pedicles 
preserve the lateral and/or anterior cutaneous branches of the fourth intercostal 
nerve that is predominantly responsible for the nipple-areola complex sensitivity. 
In superior pedicle techniques these connections are cut. However, regardless of 
technique, sensitivity often improves after reduction mammaplasty, and this may 
be due to a release of a chronic traction injury to the nerve fibres in breast 
hypertrophy (Gonzalez et al. 1993a, Slezak and Dellon 1993). On the other hand, 
patients rarely complain about reduced sensitivity. Nevertheless, preserving the 
sensitivity and hence the sexuality of the nipple-areola complex should be 
considered as an important criterion in the selection of reduction mammaplasty 
technique (Thibaudeau et al. 2010). 
Screening for breast cancer does not seem to be affected by reduction 
mammaplasty (Muir et al. 2010). However, fat necrosis may cause a palpable mass 
or radiographic features suggesting breast cancer (Mandrekas et al. 1994, Miller et 
al. 1998). Breast reduction itself may diminish the risk of breast cancer (Brown et 
al. 1999a). A lower incidence of breast cancer after reduction mammaplasty is not 
explained by a different location of breast cancer or breast tissue density (Muir et 
al. 2010). However, it has been found that women who have had breast reduction 
have an overall decrease in most cancers when compared with women in the 
general population (Boice et al. 1997, Boice et al. 2000, Fryzek et al. 2006). 
5.3 Breast dimension assessment 
Publications on comprehensive breast dimension assessment are infrequent. The 
few that are available include measurements of aesthetically perfect breasts or a 
clinical application for determining the breast augmentation volume required (Penn 
1955, Westreich 1997), descriptions of breast dimensions in women with a variety 
of breast morphologies (Smith et al. 1986), comparisons of women with normal-
sized breasts and women who seek breast reduction (Brown et al. 1999b), and a 
development of a formula including key breast dimensions for volume 
determination in breast hypertrophy (Sigurdson and Kirkland 2006). Others have 
utilised breast dimensions to establish formulas for resection weight estimation in 
reduction mammaplasty (Sommer et al. 2002, Descamps et al. 2008). 
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5.4 Reduction mammaplasty techniques 
5.4.1 History of reduction mammaplasty techniques 
More than 100 reduction mammaplasty techniques have been described (Daane and 
Rockwell 1999). However, in contrast to inventing new ideas, old ones are rather 
found and refined (Hall-Findlay 2002a). The evolution from a simple glandural 
reduction to include also nipple transposition on a pedicle and glandular 
remodelling lasted to the early 1930s (Lalardrie and Mouly 1978). Although the 
Biesenberger technique (Biesenberger 1928) had a high incidence of skin and 
nipple necrosis due to wide undermining, it remained the most popular breast 
reduction technique until the 1960s (Daane and Rockwell 1999). The beginning of 
the era of modern breast reduction techniques was in the early 1960s when an 
extensive separation of skin and gland was discarded and the nipple was transposed 
on a dermoglandular pedicle (Strombeck 1960, Dufourmentel and Mouly 1961, 
Pitanguy 1962, Skoog 1963, Pitanguy 1967). Only breast reduction with free nipple 
transplantation has remained from the earlier years as a choice for extreme cases 
(Thorek 1945). Due to the numerous published reduction mammaplasty techniques, 
an exhaustive review is beyond the scope of this thesis. Therefore, an overview of 
the most commonly used techniques is presented below. 
5.4.2 Classification of modern reduction mammaplasty 
techniques 
A classification of modern reduction mammaplasty techniques can be based on 
produced scars and nipple transposition pedicle patterns (Andrades and Prado 
2008). The pedicle can be superior, medial, inferior, lateral, central, bipedicled 
(horisontal or vertical), or combined. The scars can include a classic inverted T, a 
scar with a shorter submammary portion (short T, L, or J), vertical, horisontal, or 
periareolar. The pedicle direction and scar type can be chosen independently (Hall-
Findlay 2002a). Because the most visible disadvantage of breast reduction is the 
scars, a practical approach is to base the classification on the scar patterns. Within 
these, different pedicles can be used to transpose the nipple and this has an impact 
on how the shaping of the breast tissue takes place. The subsequent event of breast 
remodelling after the operation is dependent on the technique chosen. A vertical 
breast reduction has the ability to narrow the breast and increase breast projection, 
whereas a horizontal reduction tends to flatten and easily broaden the breast (Hall-
Findlay 2002a). 
5.4.3 Inverted T scar reduction mammaplasty 
The inverted T scar reduction mammaplasty has been a widely applied scar pattern. 
Several authors have successfully utilised this scar pattern in horizontal bi-pedicled 
(Strombeck 1960), vertical bi-pedicled (McKissock 1972, McKissock 1976), 
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central (Hester et al. 1985, Hester and Cukic 1988), and inferior pedicle reduction 
mammaplasty (Ribeiro 1975, Courtiss and Goldwyn 1977, Robbins 1977, 
Georgiade et al. 1979, Reich 1979). Of these, the inferior dermoglandular pedicle 
has been most widely used. In this technique the circulation to pedicle comes from 
the lateral thoracic, intercostals and internal mammary arteries and is therefore very 
reliable. A thin layer of tissue should, however, be left over the pectoralis fascia to 
preserve these vessels and the accompanied neural structures. The technique can be 
applied to breasts of most sizes. In very large breasts or breasts with extreme 
ptosis, resection may not be adequate and, therefore, a free nipple graft is indicated. 
Lateral resection must be appropriate enough, but tissue must be preserved 
medially for cleavage. The inferior pedicle has been the most common technique 
applied for breast reduction (Iwuagwu et al. 2006b, Nelson et al. 2008, Okoro et al. 
2008). However, the scars are extensive, and there is a tendency towards 
hypertrophic scarring in the inframammary portion. The breast shape can be 
somewhat box-shaped or flattened. During the remodelling, as the inferior gland 
descends and the nipple rotates upwards, a bottoming-out may result in an 
unsatisfactory aesthetic result (Hall-Findlay 2002a). 
5.4.4 The short scar reduction mammaplasty 
In order to shorten the extensive incisions produced by the inverted T reduction 
mammaplasty, short scar techniques (short T, L, or J) have also been developed 
(Marchac and de Olarte 1982, Marchac 1986, Regnault 1990, Chiari 2002). All 
these techniques rely on a superior dermoglandular pedicle. However, most of 
these techniques (L and J scar patterns) have somewhat complex designs and are 
therefore more difficult to learn and produce. The short T scar technique presented 
by Marchac (Marchac and de Olarte 1982, Marchac 1986) is less complicated and 
it carries the same principles as the Lejour vertical reduction mammaplasty (Lejour 
1994, Bohmert and Gabka 1997, Lejour 1999a, Lejour 1999b) and its later 
modifications (Pallua and Ermisch 2003, Hofmann et al. 2007). 
5.4.5 Vertical scar reduction mammaplasty with superior 
pedicle 
Arie and Pitanguy separately first described reduction mammaplasty with a 
superior pedicle and a vertical scar for moderately hypertrophic breasts (Arie 1957, 
Pitanguy 1962, Pitanguy 1967). However, for larger resections, a conversion to an 
inverted T scar was required. Nevertheless, the first approach to superior pedicle 
mammaplasty was made as early as in the 1920s (Dartigues 1925, Schwarzmann 
1930). 
Lassus performed a vertical scar reduction mammaplasty with a superior pedicle 
in 1964, described it in 1970, and modified the procedure to its final form in the 
mid 1980s (Lassus 1970, Lassus 1987, Lassus 1996, Lassus 1999). In this 
technique, a central wedge resection is performed without skin undermining. The 
vertical scar length varies according to the areola-inframammary distance, keeping 
in mind that it should end 3–7 cm above the inframammary fold (depending on the 
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breast size), because in this technique the inframammary fold ascends 
postoperatively. The superior pedicle should not be lifted more than 9 cm to avoid 
nipple necrosis; in such cases an alternative technique should be considered. The 
pedicle is thinned to contain 0.5–1 cm of glandural tissue. The glandural tissue 
beneath the lifted pedicle is included in the en bloc resection. The final adjustment 
of shaping is done by additional resections planned in a sitting position after 
temporary skin closure. Liposuction is not used. 
Lejour developed a modification of the technique by Lassus in the late 1980s 
and published it in 1990 (Lejour 1994, Bohmert and Gabka 1997, Lejour 1999a, 
Lejour 1999b). The technique includes three principles differing from the 
technique of Lassus: wide lower skin undermining to allow skin retraction and to 
permit shorter scars, overcorrection in order to promote improved results in the 
long term, and use of liposuction in shaping the breast and in reducing extra tissue 
sensitive to weight changes. Lejour starts the operation with liposuction. However, 
care is taken not to aspirate the medial and lateral pillars too soft in order to make 
suturing them together easier. After lateral incisions, a wide skin undermining is 
performed laterally, medially and inferiorly. The future periareolar area is left 
intact. A central resection is performed at the level of the third intercostal space, 
creating a lateral and medial pillar. The pedicle can be thinned to 2–3 cm. An upper 
central anchoring suture is placed to elevate the retroareolar tissue to the superior 
dissection space. This suture was originally placed lower in the gland, but Lejour 
later modified it to be placed at the level of the upper margin of the areola. The 
pillars are sutured together with three or four sutures of slowly absorbable material. 
The sutures are placed anteriorly, starting below the areola, and progressively 
taking deeper bites when moving downward. This produces the conical shape of 
the breast. The skin is evenly gathered to shorten the scar. For resections of more 
than 1000 g another technique is recommended, especially in obese and older 
patients. 
5.4.6 Vertical scar reduction mammaplasty with medial pedicle 
After an early experience with Lejour’s vertical reduction mammaplasty, Hall-
Findlay developed a simplified vertical reduction mammaplasty technique (Hall-
Findlay 1999, Hall-Findlay 2002a, Hall-Findlay 2002b). The nipple-areola 
complex is based on a medial dermoglandular pedicle that is easier inset and has a 
more reliable circulation, especially in larger resections. The thicker non-
undermined pedicle, along with the fact that the pectoralis fascia is not exposed 
during resection, leads also to better sensation. However, vascular and neural 
elements of the pedicle have later been demonstrated to be located just below the 
dermis (Le Roux et al. 2009), and de-epitelisation should therefore be performed 
with caution. The vertical scar ends two to six cm above the inframammary fold 
depending on the breast size. Skin undermining is done only inferiorly to the 
inframammary fold. Pectoralis fascia sutures are not normally used to inset the 
pedicle. The medial and lateral glandular pillars are sutured together at the midline 
and are responsible for shaping the breast. Liposuction is applied for possible 
lateral fullness infrequently. When compared to the Wise pattern inferior pedicle 
technique, the Hall-Findlay technique reduces scarring, requires a shorter operative 
time, and is not more difficult to learn (Serra et al. 2010). Overall, the breast shape 
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is better when compared to the inferior pedicle technique and it is retained in long-
term follow-up. However, others have noted persistent inferior dog-ear or teardrop 
deformity, and/or lateral deviation of the nipple as well as and axillary fullness, and 
have therefore modified the technique to address these issues (Chen et al. 2003, 
Chen et al. 2004). 
5.4.7 Vertical reduction mammaplasty in large resections 
More recently, several authors have applied vertical breast reduction even to large 
resections (Pallua and Ermisch 2003, Poell 2004, Lista and Ahmad 2006, Hofmann 
et al. 2007, Ahmad and Lista 2008, Amin et al. 2010, Serra et al. 2010). In order to 
achieve more tissue resection, Lista and Ahmad (Lista and Ahmad 2006) have 
modified the Hall-Findlay technique to extend the excision more deeply into the 
skin superiorly and laterally. They also maintain all the skin flaps at a thickness of 
2.5 cm in contrast to Hall-Findlay. However, they also thin the medial pedicle 
when needed. The upper border of the nipple-areola complex is planned 
preoperatively at the level of the inframammary crease, as the nipple-areola 
complex tends to rise an average of 1 cm after the operation (Ahmad and Lista 
2008). Others have also recommended fixation of the submammary fold in large 
resections (Hofmann et al. 2007). When the contractibility of the skin is not 
satisfactory, lateral extension of the wound in the submammary fold, accompanied 
with extra skin excision, is also recommended (Pallua and Ermisch 2003, Hofmann 
et al. 2007). 
5.4.8 Other vertical scar reduction mammaplasty techniques 
To reduce long scars created in inverted T inferior pedicle reduction mammaplasty 
and to provide a better long-lasting shape without pseudoptosis, a short scar 
periareolar inferior pedicle reduction mammaplasty (SPAIR) was introduced 
(Hammond 1999, Hammond 2002). In this technique, the skin envelope is tailored 
during the operation and the resulting scar is vertical in most cases. A strong 
gathering periareolar suture is used. In addition securing sutures to the pectoralis 
fascia are used to create and secure the breast shape. 
Circumvertical reduction mammaplasty with a superomedial pedicle is an 
evolution of vertical reduction mammaplasty techniques (Spear and Howard 2003). 
It utilises the skin markings similar to SPAIR with a superomedial pedicle similar 
to Hall-Findlay. Other techniques using various pedicles with periareolar and 
vertical openings have also been introduced (Van Thienen 2002, Mottura 2003, 
Atiyeh et al. 2005). 
A resection through a periareolar incision for reduction mammaplasty was 
presented in the late 1980s (Benelli 1990). The nipple-areola complex is situated 
on a superior dermoglandular flap that is fixed to the pectoralis fascia superiorly. 
Lateral and medial glandular flaps are created after the resection and sutured 
together with a full breast-lacing suture. A hyperconvex shape is common shortly 
after the operation. Skin and glandular undermining is minimised.  
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Another procedure utilises a centrally based pedicle (Goes 1996, Goes 2003). In 
this technique, periareolar de-epithelialised skin acts as a support to the breast 
shape. The inclusion of an absorbable mesh support over this circular dermal flap 
further adds support to the breast. The skin undermining is wide. Glandular 
resection is performed superiorly and inferiorly. 
5.4.9 Reduction mammaplasty with the free nipple graft 
In extreme cases the free nipple graft reduction mammaplasty can be applied for 
patients with large ptotic breasts with no pleasurable nipple sensation (Clarkson 
1950, Thorek 1963, Oneal et al. 1991, Koger et al. 1994). Overall, patients with 
unreliable or unpredictable nipple-areolar blood circulation on a dermoglandular 
pedicle are candidates for free nipple reduction mammaplasty (Oneal et al. 1991, 
Ahmed and Kolhe 2000). However, the operation is contraindicated if breast-
feeding is planned in the future. The operation can be performed faster, which 
increases safety in higher-risk patients. An inverted T scar pattern is used and the 
free nipple graft is placed on the preoperatively positioned and de-epithelialised 
area. 
5.4.10 Liposuction reduction mammaplasty 
Liposuction has been introduced as an alternative method to traditional excision 
reduction mammaplasty (Gray 1998, Matarasso 2000, Gray 2001, Matarasso 2002, 
Moskovitz et al. 2004, Moskovitz et al. 2007). It is useful in scar-prone populations 
with darker skin. Liposuction can successfully reduce the breast volume by up to 2 
litres. However, ptosis correction cannot be achieved or controlled as in 
conventional reduction mammaplasty, although some centimetres of mastopexia 
effect is obtained (Moskovitz et al. 2007). The technique is ideal for patients who 
complain about breast size and/or weight with or without ptosis-related issues. 
Patients issuing only ptosis complaints are not candidates for liposuction reduction 
mammaplasty. 
5.4.11 Complications 
Reduction mammaplasty is commonly associated with minor complications, such 
as local wound healing problems, due to long wounds and extensive raw tissue 
surfaces.  More serious complications are fortunately rare. Systemic complications 
include sepsis, deep venous and/or pulmonary embolism, and pneumonia. Major 
local complications include haematoma requiring evacuation with or without blood 
transfusion, extensive skin or nipple necrosis, and deep infection (often due to fat 
necrosis). More common minor complications include haemorrhage without the 
need of surgical treatment, superficial opening of the wounds, superficial infection, 
suture material fistulas, minor skin edge necrosis or epidermolysis. 
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The need for venous thromboembolism chemoprofylaxis is determined by 
procedure and patient-related risk factors (Young and Watson 2006). Preoperative 
antibiotic prophylaxis to prevent postoperative infections has been found effective 
and safe (Tejirian et al. 2006, Throckmorton et al. 2009). 
An inevitable consequence of the operation is the scars. The length of scars 
depends on the technique applied, as discussed in the reduction mammaplasty 
techniques above. However, there are individual differences in scarring. 
Hypertrophy or widening of the scars can cause aesthetically unpleasant results. 
Although scar problems cannot be directly categorised as a complication, it is a 
common reason for patient dissatisfaction or concern (Sprole et al. 2007). 
In a Finnish patient population (n = 273) complications were found to be 
frequent (Setälä et al. 2007). Although every other patient had a complication, most 
of them were minor. Systemic complications such as sepsis, deep venous 
thrombosis or pulmonary embolism were not encountered. However, four percent 
of the patients had a haematoma requiring evacuation. Superficial infections were 
the most common (26%) and a deep infection was treated in nine percent of the 
patients. Almost 1/5 of the patients had some degree of skin necrosis and nine 
percent required revision surgery because of wound opening or skin and/or fat 
necrosis. The most frequent (13%) subsequent operations were for scars and 
puckers or liposuction for minor irregularities. 
Other studies have also presented complication rates of 15%–53% (Cunningham 
et al. 2005, Hofmann et al. 2007, Roehl et al. 2008, Cardenas-Camarena 2009, 
Henry et al. 2009, Shah et al. 2010). The developers of the various techniques have 
shown somewhat lower rates (Lassus 1996, Lejour 1999b, Hammond 2002). 
Intraoperative hypotension has been found to be associated with postoperative 
haematoma (Henry et al. 2009). Some have not found obesity to increase 
complication rates (Setälä et al. 2007, Roehl et al. 2008), while others have 
suggested a higher body mass index to be associated with poorer outcome (Platt et 
al. 2003, O'Grady et al. 2005, Villani et al. 2009, Shah et al. 2010). 
A direct comparison of complications in different techniques is difficult because 
the selection of the technique depends on the amount of resected tissue, skin 
elasticity, patient age, co-morbidities and degree of ptosis. However, after an 
appropriate learning curve and technical adjustments, vertical scar techniques with 
various pedicles seem to be as safe as the traditional inferior pedicle technique 
(Beer et al. 2004, Poell 2004, Lista and Ahmad 2006, Spector et al. 2006, Hofmann 
et al. 2007, Spector and Karp 2007). 
5.4.12 Current trends in reduction mammaplasty techniques 
An inferior pedicle with the inverted T scar pattern is still the most used technique 
in the United States, Canada, the United Kingdom and Ireland where it is used in 
2/3–3/4 of all cases (Iwuagwu et al. 2006b, Nelson et al. 2008, Okoro et al. 2008). 
However, vertical short scar techniques have gradually gained popularity, probably 
among the younger plastic surgeons, and constitute 1/10–1/4 of all procedures. In 
Canada the technique of Hall-Findlay is popular, whereas in Europe the 
modifications of the Lejour technique are common. In Finland probably 2/3 of the 
procedures are done with the inferior pedicle and inverted T scar, whereas in the 
remaining 1/3 a superior or superomedial pedicle is used mainly with a vertical 
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scar (Setälä et al. 2007). The inferior pedicle with an inverted T scar is more likely 
to be selected by a junior surgeon or when the resection exceeds 500 grams. 
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6 AIMS OF THE STUDY 
In this thesis, the health burden of breast hypertrophy and the effects of reduction 
mammaplasty are studied. 
 
The specific aims of the present study were: 
 
1. To assess how reduction mammaplasty affects patients’ health-related 
quality of life and physical symptoms in terms of breast-associated 
symptoms and pain. 
 
2. To assess how reduction mammaplasty affects patients’ psychological 
symptoms in terms of depression, anxiety and self-esteem. 
 
3. To compare the health burden of symptomatic breast hypertrophy to the 
age-standardised general population. 
 
4. To compare the loss of quality of life caused by symptomatic breast 
hypertrophy to patient populations with major joint arthrosis. 
 
5. To compare the effects (in terms of quality of life) of reduction 
mammaplasty to patients who have undergone major joint replacement 
surgery. 
 
6. To look for factors affecting the outcome of reduction mammaplasty. 
 
7. To assess the medium-term (two to five years’) results of reduction 
mammaplasty. 
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7 PATIENTS AND METHODS 
7.1 Patients (Studies I–V) 
In August 2004 approximately 300 female patients were on the waiting list for 
bilateral reduction mammaplasty in the Hospital District of Helsinki and Uusimaa, 
Finland. The patients were approached by information letters and were asked to 
participate in the study. This thesis comprises eighty-two patients that agreed to 
attend the first examination. The patients were randomised either to be operated on 
(40 patients) or to be followed up (42 patients). The patients were operated on by 
plastic surgeons or trainees at the Department of Plastic Surgery at Helsinki 
University Central Hospital or at the Department of Surgery at Hyvinkää Hospital. 
Twenty-nine patients in the operative group and 35 patients in the non-operative 
group attended the follow-up and were included in the final statistical analysis 
(Studies I–IV). The baseline quality of life information of all 82 patients was 
compared to the age-standardised general population (Study II). The quality of life 
data of the twenty-nine patients who were operated on were compared to age-
standardised population norms at both baseline and follow-up and to major joint 
replacement patient populations (Study II). In order to identify factors affecting the 
outcome, the data of the 29 operated patients was analysed (Study IV). All patients 
of the randomised trial who were eventually operated on (73 patients) were 
assessed for the medium-term follow-up results (Study V). 
7.2 Power analysis 
As part of the study plan power analysis, based on expected changes in values of 
the quality of life questionnaire SF-36 (Collins et al. 2002), was carried out to 
determine adequate patient sample sizes for the prospective randomised study. 
Power (1-β) was set at 0.9 and α ≤ 0.01. As a result, a target of 45 patients and a 
minimum of 30 patients in both groups were considered sufficient. With a total 
number of 82 patients participating in the study, this aim was achieved. 
7.3 Randomisation 
In order to control possible confounding factors, patients’ age, height, weight and 
mean breast volume [(right breast volume + left breast volume): 2] were entered 
into a file in a coded format. The patients were grouped and ordered within the 
groups by age, height, weight and mean breast volume, respectively. Cut-off points 
were derived from a basic analysis of the data (Table 2). Nineteen groups were 
formed with two to seven patients in each. Ten patients were left as singles not 
having a group match based on the stratification criteria mentioned above. After 
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this, stratified randomisation was applied to allocate patients to either the operative 
(A) or the non-operative group (B) by picking the combination AB or BA from a 
random seed list. From groups with odd numbers of patients, one patient (last in the 
group list) was left over. At this phase 64 patients were randomised and 18 patients 
were not. The remaining patients were randomised by the minimizing method. 
With this method, the best option for group balance was calculated and the patient 
was grouped (A or B) based on this value. If the situation was a draw, the grouping 
was made by picking the combination AB or BA from the random seed list and by 
using the first letter. The patients were randomised by means of the minimizing 
method in the previously set order (stratification), and each randomised patient was 
taken into account in the calculation for the following patient. By these two 
methods, 40 patients were randomised to the operative group (A) and 42 patients to 
the non-operative group (B). 
 
 
     
Table 2. Factors and cut-off points used for stratified randomisation. 
 
     
Factor Cut-off points 
     
          
Age (years) < 35  35–45  45–55  > 55  
Height (cm) < 162    > 162  
Weight (kg) < 70  70–90   > 90  
Breast volume (litres) < 1.35    > 1.35  
          
     
7.4 Questionnaires (Studies I–V) 
Questionnaires measuring different aspects of the effects of reduction 
mammaplasty were used to reach an objective and a comprehensive picture of the 
results. Because none of the generic quality of life instruments available can be 
considered as a golden standard or superior to others, we wanted to clarify the 
results by using two quality of life instruments complementing each other, as 
recommended in the literature (Hawthorne et al. 2001). As a condition-specific 
element, breast-related symptoms were evaluated. Pain is a central symptom and 
was therefore approached separately. The psychological aspects of reduction 
mammaplasty were also assessed with a mood questionnaire. 
7.4.1 SF-36 (Studies I and IV) 
The Short Form-36 Health Survey (SF-36) is a validated and widely used 
questionnaire to assess health-related quality of life. It contains 36 items forming 
eight health subscales (physical function and activities, daily activities, emotional 
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status, social activities, mental health, vitality and energy, pain and general health), 
two summary scores (physical health and mental health), and a single health Utility 
Index Score (SF-6D) (Ware et al. 1993, 2000, Ware and Kosinski 2001). Higher 
scores represent better health. We used the Utility Index Score (SF-6D) to 
demonstrate the changes as a whole, but also the Physical and Mental Summary 
Scores to demonstrate changes separately for physical and mental functions. The 
SF-6D ranges from 0.29 to 1.00, and 0.033 is considered to be the minimal 
clinically important difference (Walters and Brazier 2003). The two summary 
scores represent a norm-based scoring with a mean value of 50 and a standard 
deviation of 10. Minimal clinically important differences have not been established 
for the summary scores. For this reason, we settled on using a half standard 
deviation as the minimal clinically important difference as suggested (Sloan et al. 
2003). 
7.4.2 15D (Studies I–II and IV–V) 
15D is another generic and standardised questionnaire of health-related quality of 
life that also includes both profile and a single index score measures (Sintonen 
2001). It consists of 15 dimensions: breathing, mental function, speech 
(communication), vision, mobility, usual activities, vitality, hearing, eating, 
elimination, sleeping, distress, discomfort and symptoms, sexual activity, and 
depression. For each dimension, the respondent must choose one of the five levels 
that best describes his/her state of health at the moment (the best level = 1; the 
worst level = 5). The valuation system of the 15D is based on an application of the 
multi-attribute utility theory. A set of utility or preference weights has been elicited 
from the general public through a 3-stage valuation procedure. These are used to 
generate the dimension level values and the overall utility score – i.e., the 15D 
score (single index number) over all the dimensions on a scale of 0–1. The 
maximum score is 1 (no problems on any dimension) and minimum score 0 (equal 
to being dead). The minimal clinically important difference in the 15D score is 
considered to be 0.03. The 15D quality of life questionnaire compares favourably 
with other similar instruments in most of the important properties (Sintonen 1995, 
Stavem 1999, Hawthorne et al. 2001, Sintonen 2001, Moock and Kohlmann 2008). 
15D has been developed and widely used in Finland and was therefore chosen as 
the second quality of life instrument to be used in this study. 
7.4.3 FBAS (Studies I and IV–V) 
The Finnish Breast-Associated Symptoms (FBAS) questionnaire evaluates 
symptoms commonly associated with breast hypertrophy. The English version of 
the Breast-Related Symptoms Questionnaire (BRSQ) has been validated (Kerrigan 
et al. 2001). Our questionnaire is a modification of this questionnaire translated 
into Finnish. In the questionnaire, patients are asked 13 questions on subjects 
including upper back pain, difficulties in finding clothing, headaches, breast pain, 
lower back pain, intertrigo, painful brassiere strap grooves, difficulties in 
participating in sports, neck pain, shoulder pain, difficulties in running, pain or 
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numbness in the hands, and arm pain. The categorical choices for answers are “all 
of the time”, “most of the time”, “some of the time”, “a little of the time”, and 
“none of the time”. A single Breast-Associated Symptoms Score (with equal 
weights for all questions) ranging from zero to 100 was calculated for statistical 
evaluation. Higher scores indicate more symptoms. 
7.4.4 FPQ (Studies I and IV) 
The Finnish Pain Questionnaire (FPQ) contains word groups describing pain 
(Ketovuori and Pontinen 1981). The words have a quantified measure ranging from 
zero to 100 for statistical analysis. A change from one word to another within a 
group is considered clinically important. As a quantified measure, this change 
ranges from eight to 30 with a mean of 18 and was used as the minimal clinically 
important difference. Pain evaluation was specified to the upper body only. A 
single pain score (mean pain for a word group) was calculated for statistical 
analysis. Higher scores indicate more pain. 
7.4.5 RBDI (Studies III–V) 
The RBDI mood questionnaire (Raitasalo 2007) is Raitasalo’s modification of the 
short form of the Beck Depression Inventory (BDI) (Beck and Beck 1972, Beck et 
al. 1974), and has been used in Finland for nearly 30 years. It has 13 questions for 
depression and one for anxiety. Evaluation of self-esteem is included in all 14 
questions. The depression score ranges from zero to 39 points. Five to seven points 
refer to mild depression, eight to fifteen points to moderate depression, and over 
sixteen points to severe depression. Anxiety has four categories (0 = none, 1 = 
mild, 2 = moderate, and 3 = severe anxiety). The self-esteem scores range from 
zero to fourteen points. Extremely high scores of self-esteem may indicate a manic 
condition. 
The questionnaire is useful in measuring depression and self-esteem among 
adults, working people, the elderly, students, schoolchildren, those with 
psychosomatic symptoms, those in rehabilitation, and patients with major 
depressive disorders (Kaltiala-Heino et al. 1999, Hietanen et al. 2001, Raitasalo 
2007). In the Finnish series the internal consistency of the depression scale ranges 
between 0.66 and 0.93, and of the self-esteem scale between 0.76 and 0.84. In the 
adult population, the depression scale correlates with the original Beck Depression 
Inventory at 0.88 in an unselected population and 0.90 among those with a major 
depressive disorder, and with the Hamilton Rating Scale for Depression (Ham-D) 
at 0.60 and 0.82, respectively (Raitasalo 2007). 
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7.5 Breast measurements (Studies I–IV) 
All breast dimension measurements were taken in a normal standing position with 
the shoulders back and the head facing straight ahead. Breast volume was measured 
with plastic cup devices. Cup volumes ranged from 150 ml to 2,700 ml, with 
intervals from 30 ml to 200 ml correspondingly to increasing volume. When breast 
volume fell between the cup volumes, an estimate of the accurate volume was 
made (by visual partition of the interval into two to four divisions). The 
anthropometric measurements taken were chest circumference at the level of the 
inframammary crease and breast circumference at the level of the nipples, as well 
as the distance from the clavicle to the nipple, from the sternal notch to the nipple, 
from the nipple to the midline and from the nipple to the inframammary crease, in 
addition to the horisontal diameter of the areola. Measurements were taken from 
the upper border of the clavicle 5 cm lateral from the sternoclavicular joint and 
from and to the center of the nipple. 
7.6 Statistical analysis (Studies I–V) 
The data were analysed with the SPSS. The basic scoring of SF-36 was made 
with SF Health Outcomes™ Scoring Software. The algorithm for the basic scoring 
of 15D ran on SPSS® was obtained from the developer of the instrument. 
Kolmogorov-Smirnov and Shapiro-Wilk tests were applied to screen normality and 
Levene’s test to screen equality of variances. 
In studies I–V, the independent-samples t test or paired t test was used for 
continuous variables meeting the assumption of normally distributed data. For data 
not meeting the assumption of normal distributions, or for categorical values, the 
Mann-Whitney U test or the Wilcoxon signed rank test was applied. The Chi 
square test or McNemar test was used to compare patient proportions. Fisher’s 
exact test was applied when appropriate. Probabilities of less than 0.05 or less than 
0.01 were accepted as significant, depending on the study setting. To control 
possible false positive findings due to multiple statistical testing, the Bonferroni 
correction was applied when needed. 
In Study I, analysis of covariance (ANCOVA) was applied for instrumental 
comparison between the two patient groups. The F-test probability value for 
entering and removal was 0.05 and 0.1, respectively. The first examination value of 
a particular instrument was included in the model. According to the randomisation 
method, covariates (age, height, weight and mean breast volume) were tested for 
inclusion in the models. Sixty-four patients who completed the follow-up were 
included in the statistical analysis for comparison of the operative and non-
operative group. The confidence level chosen was 95%. Probabilities of less than 
0.01 were accepted as significant. 
In Study II, an age-standardised comparison to the general female population 
was made for 82 patients at baseline and, for the operated 29 patients, separately at 
baseline and follow-up. Simple linear regression analysis was used to establish the 
mean difference in the 15D score from baseline to six months postoperatively 
between the groups of patients, adjusted for age and baseline 15D score. In this 
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way the operated 29 patients were also compared to those who had received a joint 
replacement. Probabilities of less than 0.05 were accepted as significant. 
In Study III, the depression and anxiety categories were dichotomised by 
combining the mild, moderate and severe categories into a “symptomatic” category 
for statistical comparison. Probabilities of less than 0.05 were accepted as 
significant. 
In Study IV, simple linear regression was applied to assess correlations between 
outcome measure changes and patient-related variables. A positive outcome 
measure change indicates a positive clinical outcome. The F-test probability value 
for entering and removal was 0.05 and 0.1, respectively. As a result of the 
Bonferroni correction for multiple statistical testing, a significance level of less 
than 0.006 was established as significant. 
In Study V, comparison from baseline to follow-up was made for the 62 patients 
who returned the follow-up data. The depression and anxiety categories were 
dichotomised by combining the mild, moderate and severe categories into a 
“symptomatic” category for statistical comparison. Probabilities of less than 0.01 
were accepted as significant. Age-standardised comparison to the general female 
population was made for these patients at follow-up. Probabilities of less than 0.05 
were accepted as significant. 
In order to estimate the internal responsiveness (i.e., sensitivity to change), 
effect size (ES) and standardized response mean (SRM) were calculated for each 
instrument (Thoma et al. 2005, Livingston et al. 2009). These estimates describe 
how good the used instruments were in detecting possible changes in our patient 
population. Effect size is calculated by the difference (Δ = mean follow-up score 
minus mean baseline score) divided by the standard deviation of the baseline 
scores. The standardized response mean (SRM) is the mean change scores divided 
by the standard deviation of the change scores. An effect size of less than 0.20 can 
be considered as insignificant, an effect size between 0.20 and 0.50 as small, an 
effect size between 0.50 and 0.80 as moderate, and an effect size greater than 0.80 
as large (Cohen 1977). 
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8 ETHICS 
Approval for the studies was obtained from the Surgical Ethical Research 
Committee of the Hospital District of Helsinki and Uusimaa. Patients were 
approached by means of information letters and they were asked to participate in 
the study. For Studies I–IV, possible patient questions were addressed over the 
telephone or at the fist examination. After agreement, patients signed an informed 
consent. For Study V, patients returned their consent along with the questionnaires 
by post. The study was conducted in accordance with the guidelines of the 
Declaration of Helsinki. 
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9 RESULTS 
9.1 General results (Studies I–IV) 
The characteristics of the whole patient population are presented in Table 3. Mean 
follow-up time for the operative and the non-operative (conservative) group was 
6.5 months (range 5.8–7.8) and 6.2 months (range 6.1–6.5), respectively. One 
patient in the operated group and seven patients in the conservative group did not 
want to continue in the study. Ten operations were postponed for organisational 
reasons or the patients’ preferences. As a result, 29 patients from the group 
operated on and 35 patients from the conservative group were followed. 
Withdrawals (eleven patients in the operated group and nine patients in the 
conservative group) did not differ significantly from the patients who completed 
the study (data not shown). Patients in the conservative group were operated 
shortly (2–10 months) after the follow-up examination. 
After randomisation, 29 patients were operated on with a mean intervention 
delay of 4.1 months (range 1.9–6.7). The techniques used were Strömbeck (12 
patients), superior pedicle with vertical scar (eight patients), inferior pedicle (eight 
patients), and free nipple graft (one patient). The mean weight of resection for the 
right and left breast was 655 g (range 200–1300) and 685 g (range 210–1360), 
respectively. Three patients had adjacent liposuction (total volume of 220, 80 and 
20 ml, respectively). The mean hospitalisation time was 3 days (range 2–4). 
Prophylactic medication against venous thrombosis and infection was given to 14 
and 22 patients, respectively. 
Among 29 patients, there were one (3%) systemic complication (pulmonary 
embolism) and three (10%) major local complications (two haematoma 
evacuations and one nipple necrosis). Local wound healing problems were 
common (14 patients, 48%). Twelve (41%) patients suffered a superficial opening 
of the wound. Six of these patients required antibiotics for a short period. Four 
(14%) haematomas required no surgical intervention. Three (10%) “dog-ears” 
(puckers) required later treatment and one (3%) minor nipple necrosis was revised 
shortly after the primary operation. 
9.2 General results (Study V) 
Sixty-two patients (85%) agreed to participate in the long-term follow-up study and 
returned the follow-up data. These patients were included in the final statistical 
analysis. Non-responders did not differ from responders as regards baseline 
characteristics (data not shown). The mean follow-up time was 4.0 years (range 
2.3–4.6). At the operation the mean age of the patients was 48.1 (Sd 10.4) years. 
The mean weight of resection for the right breast was 738 (Sd 398) grams and for 
the left breast 754 (Sd 375) grams. 
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Table 3. Studies I–IV. Patient population characteristics (n=82). 
  
    
Age (years), mean (Sd) 46.7 (1.0) 
Height (m), mean (Sd) 1.63 (0.06) 
Weight (kg), mean (Sd) 79.8 (12.6) 
BMI (kg/m²), mean (Sd) 30.1 (4.6) 
Smoking, n (%) 18 (22) 
Alcohol six or more doses per week, n (%) 12 (15) 
Previous breast surgery, n (%) 9 (11) 
Co-morbidities, n (%) 46 (56) 
Hypertension n (%) 20 (22) 
Diabetes, n (%) 1 (1) 
Asthma, n (%) 15 (18) 
Autoimmune disease, n (%) 6 (7) 
Psychiatric disease, n (%) 11 (13) 
Parturition, n (%) 61 (75) 
Marital status  
Married, n (%) 47 (57) 
Live-in relationship, n (%) 12 (15) 
Divorced, n (%) 7 (9) 
Widow, n (%) 2 (2) 
Single, n (%) 14 (17) 
Education  
Elementary school, n (%) 25 (31) 
Polytechnic, n (%) 44 (54) 
University, n (%) 13 (16) 
Employed, n (%)  65 (79) 
Work load physical  
office, n (%) 35 (43) 
light, n (%) 12 (15) 
moderate, n (%) 33 (40) 
heavy, n (%) 2 (2) 
  
Right breast volume (litres), mean (Sd) 1.36 (0.38) 
Left breast volume (litres), mean (Sd) 1.40 (0.39) 
Chest circumference (cm), mean (Sd) 94.5 (8.9) 
Breast circumference (cm), mean (Sd) 111.5 (10.0) 
Clavicle to nipple Right (cm), mean (Sd) 34.7 (4.2) 
Clavicle to nipple Left (cm), mean (Sd) 34.5 (4.0) 
Sternal notch to nipple Right (cm), mean (Sd) 33.7 (4.1) 
Sternal notch to nipple Left (cm), mean (Sd) 34.0 (3.9) 
Nipple to inframammary crease Right (cm), mean (Sd) 15.5 (4.1) 
Nipple to inframammary crease Left (cm), mean (Sd) 16.2 (4.0) 
Nipple to midline Right (cm), mean (Sd) 12.4 (1.7) 
Nipple to midline Left (cm), mean (Sd) 12.5 (1.8) 
Areola horisontal diameter Right (cm), mean (Sd) 7.8 (2.0) 
Areola horisontal diameter Left (cm), mean (Sd) 8.1 (1.8) 
    
  
Values are expressed as means with standard deviations (Sd) or, in categorical cases, as 
frequencies (n) with percentages (%). BMI, body mass index. 
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9.3 Effect sizes and standardized response means 
With the exception of the mental summary score of the SF-36 quality of life 
questionnaire (effect size medium, i.e. 0.5-0.8), the effect sizes of the outcome 
measures were large (i.e., over 0.8) (Table 4). 
 
 
Table 4. Effect sizes (ES) and standardized response means (SRM) for the outcome 
measures.  
      
      
Outcome measure Change (∆) Sd (baseline) Sd (∆) ES SRM 
      
      
SF-36 HRQoL 0.174 0.133 0.136 1.31 1.28 
Physical health score 9.73 8.70 6.814 1.12 1.43 
Mental health score 7.80 11.24 11.24 0.69 0.69 
15D HRQoL score 0.086 0.083 0.063 1.04 1.37 
Breast symptoms 47.94 14.97 14.45 3.20 3.32 
Pain 21.43 14.71 17.22 1.46 1.24 
Depression 3.38 3.96 2.91 0.85 1.16 
Self-esteem 3 3.19 2.38 0.94 1.26 
      
      
HRQoL, Health-Related Quality of Life; ES = ∆/Sd; SRM = ∆/Sd (∆). 
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9.4 The effects of reduction mammaplasty on quality of life 
and physical symptoms (Study I) 
For SF-6D and PCS, a statistically and clinically significant difference was found, 
with all the values within the confidence interval of difference being clinically 
important. The confidence interval of difference for the MCS was broader, with 
some of the values not being clinically important (Table 5). 
The 15D index score yielded statistically and clinically significant differences 
between the operative and the non-operative group at the second examination. All 
values within the confidence interval of difference were also clinically important.  
The 29 operated patients reported significantly fewer breast-associated 
symptoms or less pain when compared with the non-operated patients at the second 
examination. For pain, practically all the values within the confidence interval of 
difference could be considered clinically important. 
Twenty-eight patients (97%) were overall satisfied with the surgical result and 
would have had the operation again. Twenty-one patients (72%) were satisfied with 
their breast size; six patients (21%) found them too large and two patients (7%) too 
small. Twenty-three patients (79%) were satisfied with the breast shape, and six 
(21%) were unsatisfied. Five of these patients rated their breasts still too large, 
whereas one patient thought her breasts were too small postoperatively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
Table 5. Reduction mammaplasty patients’ outcome measure data at first and at second 
examinations. 
    
     
 
Operative 
group 
Non-
operative group  
 29 patients 35 patients p* (CID) 
     
    
SF-36 Utility Index Score (SF-6D)    
First examination 0.645 (0.138) 0.657 (0.131) 0.734 (-0.079 ; 0.056) 
Second examination 0.820 (0.143) 0.663 (0.136) 0.0001 (0.107 ; 0.220) 
    
SF-36 Physical Summary Score    
First examination 42.0 (8.6) 42.6 (8.9) 0.770 (-5.0 ; 3.8) 
Second examination 51.7 (7.6) 43.3 (7.8) 0.0001 (5.8 ; 11.8) 
    
SF-36 Mental Summary Score    
First examination 46.0 (12.2) 47.2 (10.5) 0.672 (-6.9 ; 4.5) 
Second examination 53.8 (8.4) 46.2 (13.1) 0.002 (3.2 ; 13.1) 
    
15D Index Score    
First examination 0.831 (0.090) 0.855 (0.076) 0.248 (-0.066 ; 0.017) 
Second examination 0.917 (0.075) 0.861 (0.087) 0.0001 (0.041 ; 0.103) 
    
Breast-Associated Symptoms Score    
First examination 59.7 (14.8) 61.4 (15.3) 0.658 (-9.2 ; 5.9) 
Second examination 11.8 (7.7) 57.9 (14.3) 0.0001 (-49.2 ;-40.7) 
    
Pain Score    
First examination 28.5 (16.6) 27.5 (13.2) 0.787 (-6.4 ; 8.5) 
Second examination 7.0 (8.4) 26.5 (13.5) 0.0001 (-25.2 ; -14.3) 
     
    
Values are mean (Sd). BMI, body mass index. SF-36, Short Form-36 quality of life questionnaire. 
15D, 15D quality of life questionnaire. *ANCOVA, CID = 95% confidence interval of difference. 
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9.5 Comparison to the general population and patients 
undergoing major joint replacement surgery (Study II) 
At baseline patients (n=82) showed significantly lower mean values for most of the 
dimensions, and lower mean 15D scores than the age-standardised general female 
population (Figure 1). The dimensions of discomfort and symptoms, distress, and 
vitality showed particularly low values. The extent of the health deficit (0.09) for 
symptomatic breast hypertrophy was well above the minimal clinically important 
difference of 0.03. A separate baseline comparison for the operated 29 patients 
demonstrated the same findings (Figure 2). Postoperatively, there was no 
difference in the mean 15D score between the operated 29 patients and the general 
population (Figure 3). 
 
 
Figure 1. The 15D profiles of all patients (n=82) at baseline, compared to the age-
standardised general female population (n=2532); * significantly worse HRQoL 
among the patients than in the general population at the p < 0.05 level, ** at the p < 
0.01, and *** at the p < 0.001 level. 
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Figure 2. The 15D profiles of the operated patients (n=29) at baseline, 
compared to the age-standardised general female population (n=2497); * 
significantly worse HRQoL among the patients than the general population at the p 
< 0.05 level, ** at the p < 0.01, and *** at the p < 0.001 level. 
 
 
 
Figure 3. The 15D profiles of the operated patients (n=29) at follow-up, compared 
to the age-standardised general female population (n=2468); * significantly better 
HRQoL among the patients than the general population at the p < 0.05 level. 
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When compared preoperatively, patients who had undergone reduction 
mammaplasty (this study, n=82) and those who had undergone major joint 
replacement (Räsänen et al. 2007) showed no differences in the mean 15D score 
(adjusted for age with linear regression analysis). Postoperatively, both reduction 
mammaplasty (p = 0.03) and total hip replacement (p = 0.002) yielded a greater 
improvement in health-related QoL than total knee replacement (adjusted for age 
and baseline 15D score with regression analysis). The adjusted changes in the 15D 
score were 0.064 for reduction mammaplasty (n=29), 0.055 for total hip joint 
replacement (n=95) and 0.022 for total knee joint replacement (n=102). The 
intervention effect of reduction mammaplasty (0.064) was also well above the 
minimal clinically important difference of 0.03. 
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9.6 The effects of reduction mammaplasty on psychological 
symptoms (Study III) 
At the first examination 33 patients (52%) were not depressed, and 16 patients 
(25%) suffered from mild, 14 from moderate (22%), and one from (2%) severe 
depression. Twenty-eight patients (44%) were not anxious, while 32 patients (50%) 
had mild, three patients (5%) moderate, and one patient (2%) severe anxiety. 
Overall, only 23 (36%) of the patients showed no signs of depression or anxiety at 
baseline. There were 9 (31%) and 14 (40%) asymptomatic patients in the operative 
and conservative group at baseline, respectively. 
At the first examination the median depression score for the operated patients 
(n=29) was 5 (interquartile range 2.5–6.5) and the self-esteem score 3 (1.5–7.0). 
For the conservatively treated patients, the respective values were 4 (1.0–8.0) and 5 
(2.0–7.0). The differences were not statistically significant (p=0.63 for depression 
and p=0.22 for self-esteem, Mann Whitney U test). At the second examination, 
patients in the operative group had significantly less depression (p < 0.01) and 
higher self-esteem (p = 0.03) when compared with the conservatively treated 
group. The median depression score postoperatively for the operated patients was 0 
(interquartile range 0.0–2.5) and the self-esteem score 7 (5.5–10.0). For the 
conservatively treated patients, the respective values were 4 (0.0–7.0) and 5 (2.0–
9.0). 
At the first examination there was no difference in the proportions of depressive 
or anxious patients between the operatively (depressed 55%, anxious 62%) and the 
conservatively treated (depressed 43%, anxious 51%) group (for both p=0.45, 
Fisher’s exact test). At the second examination the proportions of both depressive 
(p < 0.01) and anxious (p = 0.04) patients differed significantly between the 
operated and the conservatively treated patients.  
Only two (7%) and three (10%) of the operated patents were depressed or 
anxious, respectively. Four out of five patients who were depressive or anxious 
preoperatively showed no signs of psychological distress postoperatively. This 
leaves only three (10%) symptomatic patients in the operative group at follow-up. 
In contrast, 15 (43%) and 12 (34%) patients were still depressed or anxious, 
respectively, in the conservatively treated group at follow-up. Eighteen (51%) 
patients were asymptomatic. 
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9.7 Factors affecting the outcome of reduction mammaplasty 
(Study IV) 
Patients who were anxious preoperatively had somewhat more improvement in the 
quality of life index scores when compared to those who were not anxious 
preoperatively (SF-6D, standardised β = 0.535, p = 0.001; and 15D, β = 0.592, p < 
0.001). However, when the mental component summary scores (MCS) of SF-36 
were considered, the effect was the opposite: anxious patients having less 
improvement (β = -0.719, p < 0.001). A similar trend was found with the self-
esteem scores of RBDI (β = -0.387, p = 0.024). Preoperatively anxious patients 
experienced more improvement in the depression score (β = 0.514, p = 0.002). The 
postoperative “vertical nipple deviation from normal” (ptosis) showed a weak 
tendency towards less improvement in depression score (β = -0.339, p = 0.036). 
Patients with physically demanding work experienced somewhat more 
improvement in SF-6D scores (β = 0.488, p = 0.003) and demonstrated a trend 
towards less improvement in the mental component summary scores of SF-36 (β = 
-0.369, p = 0.010). Patients with a single household had a tendency towards less 
improvement in breast-associated symptoms when compared to patients in a 
relationship (β = 0.491, p = 0.007). Patients with a body mass index of over 25 
tended to experience less improvement in self-esteem (β = 0.390, p = 0.023). For 
the physical component summary (PCS) of SF-36 or the pain score, no regression 
models were established as all the tested factors exceeded the limit of statistical 
significance. 
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9.8 The medium-term results of reduction mammaplasty 
(Study V) 
The mean follow-up time was 4 years (range 2–5 years). Preoperatively, patients 
had a significantly inferior quality of life when compared to the age-standardised 
population (Figure 4). Especially the dimensions of breathing, sleeping, discomfort 
and symptoms, as well as depression, distress, vitality and sexual activity 
demonstrated inferior values. This health burden was removed after reduction 
mammaplasty. Postoperatively, the dimensions for usual activities and mental 
function showed somewhat better values when compared to the age-standardised 
population (Figure 5). 
At follow-up, patients had fewer breast-associated symptoms, less depression 
and anxiety and a better quality of life and self-esteem when compared to the 
preoperative situation (Table 6). The intervention effect of reduction mammaplasty 
in terms of quality of life (0.083) was more than two and a half times the 
considered minimal clinically important difference (0.03) of the index score of 
15D. 
 
 
Figure 4. The 15D profiles at baseline (n=62), compared to the age-standardised 
general female population (n=2468); * significantly worse HRQoL in the patients 
than the general population at the p < 0.05 level, ** at the p < 0.01, and *** at the p 
< 0.001 level. 
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Figure 5. The 15D profiles at 2–5 years follow-up (n=62), compared to the age-
standardised general female population (n=2697); * significantly better HRQoL in 
the patients than in the general population at the p < 0.05 level, and ** at the p < 
0.01. 
 
 
 
 
Table 6. Reduction mammaplasty patients’ quality of life as well as breast-associated 
and psychological symptoms at baseline and at 2–5 years’ follow-up (n=62). 
    
    
 Baseline Follow-up p value 
    
    
15D score; mean (Sd) 0.847 
(0.081) 
0.930 
(0.074) 
< 0.001 
◊ Breast-associated symptoms score; 
mean (Sd) 
59.9 (13.4) 15.2 (11.0) < 0.001 
◊ Depression score; median 
(interquartile range) 
4 (1-6) 0 (0-3) < 0.001 
† Self-esteem score; median 
(interquartile range) 
4 (2-7) 6 (4-10) < 0.001 
† Anxious; frequency (percentage) 33 (53) 8 (13) < 0.001 
‡     
 
◊ paired t test, † Wilcoxon signed rank test, ‡ McNemar test 
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10 DISCUSSION 
10.1 General considerations 
Before the uniform criteria for access to non-emergency treatment in Finland 
(Finnish Ministry of Social Affairs and Health 2005) came into force on 1 March 
2005, the expected waiting time before a reduction mammaplasty operation in the 
Hospital District of Helsinki and Uusimaa was five to seven years. This may 
explain why our patients were several years older in comparison to previous 
prospective study populations (Shakespeare and Cole 1997, Behmand et al. 2000, 
Blomqvist et al. 2000, Collins et al. 2002, Blomqvist and Brandberg 2004, Freire et 
al. 2004, Miller et al. 2005, Thoma et al. 2005, Iwuagwu et al. 2006e, O'Blenes et 
al. 2006, Freire et al. 2007, Neto et al. 2008). In Finland, patients are usually 
advised to have their children before reduction mammaplasty to ensure successful 
breastfeeding. Furthermore, cultural differences or the more pronounced low-
prioritisation, when compared with countries with insurance coverage systems or 
criteria concerning maximum times to arrange treatment, may explain the 
difference. In addition, the criteria for referral and indications for reduction 
mammaplasty have been strict. 
When compared to two recent randomised trials, our patients were also found to 
be somewhat (Iwuagwu 2003, Iwuagwu et al. 2005, Iwuagwu et al. 2006d, 
Iwuagwu et al. 2006e) or considerably (Freire et al. 2007, Neto et al. 2008) older. 
Our patients had a higher body mass index and somewhat greater resection 
weights. These differences can be explained by reasons discussed above or by 
exclusion criteria. Freire et al. (2007) and Neto et al. (2008) excluded patients who 
were over 55 years of age or who had significant co-morbidities, regular 
medication or a body mass index over 30, as well as those who smoked. In 
contrast, we included all female patients aged 18–65 years who had bilateral 
symptomatic breast hypertrophy. Iwuagwu et al. (2006c, 2006d, 2006e) had similar 
inclusion criteria to ours. They included three and seven current smokers in their 
intervention (37 patients) and control group (36 patients), respectively. Eighteen 
patients (22%) in our study population were smokers. Because of these similarities, 
we find that the results from our randomised trial are comparable to those of 
Iwuagwu et al. (2006c, 2006d, 2006e), but less so with the results of Freire et al. 
(2007) and Neto et al. (2008). Some differences are found also in the reduction 
mammaplasty techniques applied. Iwuagwu et al. (2006c, 2006d, 2006e) used 
solely the inferior pedicle technique, whereas Freire et al. (2007) and Neto et al. 
(2008) utilised the superior or superomedial pedicle technique depending on the 
degree of ptosis. This may explain the differences in resection weights. In our sub-
studies a variety of techniques were used depending on the surgeons’ and patients’ 
preferences. 
The dropout rate (22%) in our randomised trial was quite high and may diminish 
the significance of our results (Schulz and Grimes 2002). In the other randomised 
studies the follow-up rate has been higher, varying from 89% to 100% (Iwuagwu et 
al. 2005, Iwuagwu et al. 2006c, Iwuagwu et al. 2006d, Freire et al. 2007, Neto et al. 
2008). Therefore, in comparison to others, our dropout rate yields some weakness 
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to the otherwise strong scientific evidence produced. However, we found no 
differences in the baseline characteristics of dropouts and followed patients. This 
suggests that the dropouts did not bias the results. Our study population size is 
comparable, and our follow-up time equals or exceed that of others (Iwuagwu et al. 
2005, Iwuagwu et al. 2006c, Iwuagwu et al. 2006d, Freire et al. 2007, Neto et al. 
2008). Our study population represented 22 percent of the patients on the waiting 
list with similar age distributions. We find that our results are well applicable to 
populations of Finnish breast hypertrophy patients. 
10.2 Outcome measurement in reduction mammaplasty 
The use of a comprehensive set of standardised and validated tools for assessing 
the health burden and effects of reduction mammaplasty was introduced by 
Kerrigan et al. (Kerrigan et al. 2000, Kerrigan et al. 2001). This kind of approach is 
crucial if adequate and reproducible data for decision-making purposes is to be 
presented. In addition, the use of quality of life outcome instruments enables a 
comparison of different health states and treatments (Collins 2003). In this thesis a 
set of five outcome instruments provided a reliable assessment for the effects of 
reduction mammaplasty. 
However, recently introduced, specifically developed instruments for breast 
reduction patients provide a better coverage of a larger spectrum of the morbidity 
of these patients (Sigurdson et al. 2007a, Sigurdson et al. 2007b, Klassen et al. 
2009, Pusic et al. 2009). These questionnaires do not suffer from the content 
validity limitations that the current thesis may be subject to. However, this 
limitation was compensated in our study by using a set of five questionnaires, as 
presented in detail in the Methods section. The set of questionnaires used in this 
thesis covers the same areas as the newly developed instruments. Nevertheless, the 
questionnaires – with the exception of the breast-associated symptoms 
questionnaire – have not been specifically developed for reduction mammaplasty 
patient populations, which brings about some limitations (Pusic et al. 2007a). 
Firstly, some areas not covered by the new instruments may be included in our 
questionnaires, making the interpretation of the results different. However, if these 
areas are assumed not to change after surgery (i.e., not to be related to the health 
burden of hypertrophic breasts), it can be suggested that any extra areas or 
remnants included in the questionnaires did not interfere with the results (at most, a 
weakening effect on the results would have occurred). Changes due to other 
reasons (for instance, life situations) are possible. Nevertheless, the specifically 
developed instruments have similar limitations as they also measure somewhat 
“general” areas (physical, psychosocial and sexual well-being) that may also 
change due to reasons other than breast reduction surgery. Secondly, the general 
instruments used in this thesis may have posed responsiveness (sensitivity to 
change) issues. However, with the exception of the mental summary score of the 
SF-36 quality of life questionnaire (effect size medium), the effect sizes of our 
questionnaires were large (over 0.8), suggesting that they responded adequately. 
Therefore, we find that our set of instruments was able to produce reasonable and 
adequate results. 
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10.3 The effects of reduction mammaplasty on quality of life 
and physical symptoms 
The first randomised studies published (Iwuagwu et al. 2006d, Iwuagwu et al. 
2006e) provided the long-awaited strong scientific evidence of the effects of 
reduction mammaplasty. Thereafter, subsequent publications have demonstrated 
various aspects of the value of reduction mammaplasty (Iwuagwu et al. 2005, 
Iwuagwu et al. 2006c, Iwuagwu et al. 2006d, Freire et al. 2007, Neto et al. 2008). 
Iwuagwu et al. (2006d, 2006e) utilised several outcome instruments measuring 
quality of life and psychosocial factors as an attempt to give a comprehensive and 
versatile view of the benefits of reduction mammaplasty. Others have concentrated 
more on functional capacity, pain and self-esteem, and therefore presenting 
somewhat less diverse results (Freire et al. 2007, Neto et al. 2008). However, none 
of the previous authors utilised a true condition-specific outcome instrument. All 
the instruments were otherwise designed for generic use, or originally for other 
conditions. Therefore we find that our results may provide more adequate data of 
the benefits of reduction mammaplasty. Although the breast-associated symptoms 
questionnaire we used has some content limitations (Pusic et al. 2007a, Pusic et al. 
2009), it has been noted to yield good internal and external responsiveness (Thoma 
et al. 2005). However, our questionnaire is a translation of the English version into 
Finnish. It has not been formally validated, and this is a limitation. A future 
validation work is therefore required. 
Some researchers (Iwuagwu et al. 2006d, Iwuagwu et al. 2006e) have provided 
their control group with physiotherapy. In our study the non-operative group did 
not receive any additional treatment. Although physiotherapy has not been found to 
offer permanent relief (Collins et al. 2002), this could act as an intervention 
improving the control group thus biasing the results (making the difference 
between groups smaller). In addition, Iwuagwu et al. (2006d and 2006e) used 
several outcome measures. They did not, however, take into account the risk of 
false positive findings due to multiple statistical testing. Nevertheless, their results 
demonstrated high levels of significance. 
Two publications from the same trial found that reduction mammaplasty 
significantly improved functional capacity and self-esteem, in addition to relieving 
pain in the lower back, shoulders and neck (Freire et al. 2007, Neto et al. 2008). 
Freire et al. (2007) and Neto et al. (2008) randomised 100 patients, which is more 
that in the study of Iwuagwu et al. (2006c, 2006d and 2006e) and the present thesis. 
However, the patient population was significantly different from those of Iwuagwu 
et al. (2006c, 2006d and 2006e) and our studies due to exclusion criteria. In 
addition, Freire et al. (2007) and Neto et al. (2008) also failed to demonstrate the 
improvement by a condition-specific outcome measure. Nevertheless, their results 
showed high statistical significance after the six-month follow-up period. 
In the current data, reduction mammaplasty resulted in great relief of physical 
symptoms and pain. This is demonstrated by the physical summary score of the SF-
36 and the pain score. Changes in mental health are less obvious or lacking, as 
demonstrated by the mental summary score of SF-36. These findings are supported 
by others (Miller et al. 2005, O'Blenes et al. 2006). By alleviating the physical 
complaints caused by heavy breasts, this surgical treatment provides an excellent 
improvement in health-related quality of life. However, others have noted that 
younger women have more psychological symptoms whereas older women 
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complain more about physical symptoms (Behmand et al. 2000, Sigurdson et al. 
2007b). This may explain the above-mentioned findings as the mean age of our 
patients was 47 years. Freire et al. (2007) and Neto et al. (2008) had considerably 
younger patients due to their exclusion criteria, but they did not use a psychological 
outcome measure. Iwuagwu et al. (2006c, 2006d, 2006e) had a patient population 
that was somewhat younger but otherwise comparable to ours. They used the SF-
36 quality of life questionnaire and found significant improvement in both the 
physical and the mental summary scores. The change in mental health seemed to be 
greater than in our study. However, they did not present confidence intervals to 
explore the findings, as we did in our study. 
10.4 Comparison to the general population and patients 
undergoing major joint replacement surgery 
The health deficit in patients waiting for reduction mammaplasty is considerable 
and has been demonstrated in several studies (Klassen et al. 1996a, Klassen et al. 
1996b, Shakespeare and Cole 1997, Souza Faria et al. 1999, Behmand et al. 2000, 
Blomqvist et al. 2000, Kerrigan et al. 2001, Collins et al. 2002, Blomqvist and 
Brandberg 2004, Freire et al. 2004, Miller et al. 2005, O'Blenes et al. 2006, Thoma 
et al. 2007, Tykkä et al. 2010). In our study we found that it is comparable to that 
of patients waiting for major joint arthroplasty (after standardising for age 
differences). This underlines the fact that symptomatic hypertrophic breasts cause, 
in our opinion, a true musculoskeletal pain disorder. This is also demonstrated by 
the condition-specific measure evaluating physical symptoms (Kerrigan et al. 2001, 
Collins et al. 2002, Miller et al. 2005, Thoma et al. 2007). However, recent 
research has found symptomatic breast hypertrophy to include components of 
physical, psychosocial and sexual well- being, and therefore it cannot be 
considered purely as a condition with physical complaints (Sigurdson et al. 2007a, 
Sigurdson et al. 2007b, Klassen et al. 2009, Pusic et al. 2009), although the bodily 
pain and breast-related symptoms are found to dominate (Sigurdson et al. 2007a). 
The measured health deficit caused by the morbidity (in terms of quality of life 
measured by a generic instrument) clearly exceeds the minimal clinically important 
difference and, on the other hand, reduction mammaplasty removes this deficit 
completely. 
Increasing co-morbidity is a common problem in clinical studies, particularly in 
older patients, and brings limitations to the assessment of the impact of individual 
conditions on HRQoL (Saarni et al. 2006). Major joint arthrosis usually becomes 
symptomatic in older patients, whereas hypertrophic breasts are more likely to 
cause symptoms in early adulthood. A surgical intervention that improves the 
HRQoL as well as physical, mental and social capability of young people should 
therefore not be postponed unnecessarily. However, younger women have been 
noted to have more psychological symptoms, whereas older women complain more 
about physical symptoms (Behmand et al. 2000, Sigurdson et al. 2007b). 
Nevertheless, when the pain and disease condition develops within time towards a 
more chronic condition, coexisting conditions, both physical and mental, can 
increase and cause further loss of HRQoL (van Elk et al. 2009). The overall 
approach should be focused on early intervention. This yields more illness-free or 
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illness-reduced years of life. The burden of coexisting conditions and reduced 
capacity to heal with increasing age, as shown in total joint replacement (Rissanen 
et al. 1997), can hinder rehabilitation and produce less satisfactory results.  
When compared to patients waiting for major joint arthroplastia, the quality of 
life of patients awaiting reduction mammaplasty was somewhat better 
preoperatively, when results were standardised for age. This is probably because 
fewer co-morbidities were present. This may explain why patients who have 
undergone reduction mammaplasty may experience an even greater improvement 
in HRQoL than those who have received major joint replacement, because 
significant co-morbidities do not prohibit receiving full benefit from the procedure. 
This further underlines the importance of early intervention. Furthermore, all 
secondary consequences of symptomatic hypertrophic breasts (sick leaves for 
musculosceletal symptoms, costs of pain medication and physiotherapy, etc.) are 
reduced or removed. In the end, the gain of an individual patient is much more than 
what can be calculated by means of cost-effectiveness analysis. However, defining 
cost-effectiveness offers a crucial tool for financial decision-making. 
10.5 The effects of reduction mammaplasty on psychosocial 
symptoms 
Studies on psychological changes after breast reduction have used various 
instruments, most commonly the Hospital Anxiety and Depression Scale (HADS) 
(Zigmond and Snaith 1983). In our study we used Raitasalo’s modification of the 
short form of the Beck Depression Inventory questionnaire (Raitasalo 2007). 
However, recently developed condition-specific instruments include psychosocial 
aspects perhaps obviating complementary psychological questionnaires (Sigurdson 
et al. 2007a, Sigurdson et al. 2007b, Klassen et al. 2009, Pusic et al. 2009). 
Nevertheless, psychological evaluation may be recommended preoperatively as 
some of the patients may need psychological intervention before surgery (Rubino 
et al. 2007, Kellett et al. 2008). On the other hand, additional preoperative 
information has also been found to reduce anxiety (Danino et al. 2005). 
Preoperatively we found half of the patients to be depressed or anxious, or both. 
This high psychological morbidity has also been shown by others (Guthrie et al. 
1998, Souza Faria et al. 1999, Iwuagwu et al. 2006d, Benditte-Klepetko et al. 
2007). It has been suggested that patients whose macromastia becomes 
symptomatic and who ask for reduction mammaplasty are vulnerable to adverse 
comments about the size of their breasts (Guthrie et al. 1998), and their 
interpersonal sensitivity and hostility is greater (Behmand et al. 2000). The 
increasing weight of breasts may correlate with more depressive symptoms 
(Benditte-Klepetko et al. 2007). However, there is also a correlation between 
obesity and depression (Herva et al. 2006), and so weight loss may reduce 
psychological risks (Benditte-Klepetko et al. 2007). Obesity is also associated with 
poorer self-esteem (Sarwer et al. 2005). In our patient population, four out of five 
subjects showed no signs of their preoperative depression or anxiety six months 
after reduction mammaplasty. In the conservatively treated group the incidence of 
depression remained unchanged during the follow-up period. However, the patients 
were slightly less anxious at the second examination. This may be explained by the 
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fact that they already knew their operation would come within the following 
months and felt relieved. 
Two earlier studies have reported an improvement in psychological well-being 
in patients who requested reduction mammaplasty for cosmetic reasons (Hollyman 
et al. 1986, Chahraoui et al. 2006). The results are therefore not directly 
comparable with those in our study. Nevertheless, four prospective studies (Souza 
Faria et al. 1999, Behmand et al. 2000, Borkenhagen et al. 2007, Mello et al. 2009) 
and three randomised trials (Iwuagwu et al. 2006d, Iwuagwu et al. 2006e, Neto et 
al. 2008) have reported on psychological symptoms among patients with 
symptomatic hypertrophic breasts. However, in one of the prospective studies 
(Souza Faria et al. 1999), the follow-up time was quite short for some patients, 
ranging from one month to 10 months (mean 4), and the clinical details were not 
available for comparison. Of the other three prospective studies, results ranged 
from good to somewhat weaker evidence (Behmand et al. 2000, Borkenhagen et al. 
2007, Mello et al. 2009). Two randomised trials (Iwuagwu et al. 2006d, Iwuagwu 
et al. 2006e) reported results with the same group of patients. The first report 
focused on quality of life and also introduced psychosocial changes. The other 
assessed changes in depression and anxiety. In both, breast reduction had a 
significantly good impact on quality of life, depression, anxiety, and psychosocial 
aspects. In comparison with our study, the follow-up time (four months) was 
somewhat shorter and the patients were younger, but the size of breasts, height, and 
weight of the patients were roughly similar. The third randomised study also 
showed the improvement in patients’ self-esteem after reduction mammaplasty 
(Neto et al. 2008). 
In comparison to our study, more residual anxiety postoperatively was reported 
by Souza Faria et al. (1999). In our study, the excess of depression and anxiety 
were reduced in equal amounts, but there was still some residual depression and 
anxiety left. Nevertheless, the amount was small, and comparable to “normal” 
levels in the general population (Kurki et al. 2000). 
Younger women have been noted to have more psychological symptoms 
whereas older women complain more about the physical symptoms (Behmand et 
al. 2000, Sigurdson et al. 2007b). Although our patients were older (mean age 47 
years, range 22–64), they presented significant psychological symptoms 
preoperatively. This may reflect that chronic pain may cause psychosocial 
morbidity over the years (van Elk et al. 2009). This factor may have been important 
in our patient population, as the waiting time for the operation was five to seven 
years. 
10.6 Factors affecting the outcome of reduction mammaplasty 
Past studies have suggested dissatisfaction with the outcome to be related to 
anxiety and depression (Cerovac et al. 2005, Chahraoui et al. 2006). Recent 
qualitative research has shown that psychosocial aspects are fundamental in the 
measurement of the outcome of reduction mammaplasty (Sigurdson et al. 2007a, 
Sigurdson et al. 2007b, Klassen et al. 2009, Pusic et al. 2009). In fact, less 
psychological distress preoperatively seems to improve outcome (von Soest et al. 
2006). An increasing number of co-morbid conditions have been found to have a 
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deteriorating effects on outcome (Collins et al. 2002). Some authors have 
suggested a higher body mass index to be associated with poorer clinical outcome 
(O'Grady et al. 2005, Villani et al. 2009), while others have not found obesity to 
increase complication rates (Setälä et al. 2007, Roehl et al. 2008). The quality of 
the preoperative information provided and the relationship between the patient and 
surgeon are also associated with patient satisfaction or dissatisfaction (Chahraoui et 
al. 2006). Unfortunately, preoperative information seems to be retained poorly by 
patients (Godwin 2000), but a written consent provides better understanding 
(Ashraff et al. 2006). Audiovisual material has been found to reduce anxiety and 
improve knowledge (Danino et al. 2005). 
In Study IV, we found some interesting associations between psychosocial 
factors and the outcome measure changes. Although the true effects of reduction 
mammaplasty are a result of the weight reduction of the breasts, some differences 
in the outcome are explained by patient-related factors. Anxious patients or those 
with physically demanding work improved less. The expectations of these patients 
may have been unrealistic as breast reduction is not the treatment of choice for 
psychological disorders or decreased work capacity, although it certainly reduces 
the overall physical and psychological distress. A discrepancy between patient 
expectations and the attainable benefit may have caused disappointment and a 
decrease in mental health (Montebarocci et al. 2007, Rubino et al. 2007).  
Patients with no overweight had a trend towards better improvement in self-
esteem when compared with those whose body mass index was over 25. This may 
be explained by a negative effect of overweight on self-esteem (Sarwer et al. 2005) 
and body-image (von Soest et al. 2009). However, patients with a greater body 
mass index or greater resection weight seem to gain more improvement after breast 
reduction in terms of breathing function (Sood et al. 2003, Iwuagwu et al. 2006c). 
The patients in our study weighed 0.5 kg more after the breast reduction, when an 
adjustment for the breast resection weight was made. Some authors have suggested 
a stimulus for weight loss after breast reduction (Singh et al. , O'Blenes et al. 
2006). Our follow-up time was somewhat shorter, which may explain why patients 
were not able to reach the full benefit from the procedure. On the other hand, 
patients have been strongly advised to lose weight before surgery to minimise 
complication risks and the small weight gain afterwards may be only a return to 
“normality.” However we had no objective information of the weight status before 
the first examination, and this question therefore remains unanswered to a degree. 
10.7 Medium-term results of reduction mammaplasty 
The short-term result may change over time, which is why medium and long-term 
evaluation is essential to verify the results. In this thesis medium-term results were 
collected after a mean of four years’ (range two to five years) follow-up. At this 
point possible factors affecting short-term results, as complications or euphoria, 
have subsided. Prospective long-term (i.e., 10 years or more) follow-up data on 
reduction mammaplasty is lacking. The outcome of reduction mammaplasty seems 
to remain stable at two to four years’ follow-up (Shakespeare and Postle 1999, 
Blomqvist and Brandberg 2004, O'Blenes et al. 2006). However, questions arise as 
some impairment has been noted during follow-up. Blomqvist and Brandberg 
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(2004) reported a small non-significant increase in patient-reported pain, especially 
headache, from one to three years follow-up. They concluded these changes to be 
connected to other factors than breast problems. However, a similar trend was also 
noted in patient-reported problems related to breast size and weight. 
In our study, a subgroup analysis of our previous data at six months’ follow-up 
(Studies I and III) demonstrates that the effects of breast reduction surgery remain 
stable with no significant loss during the first postoperative years. In fact, our 
medium-term follow-up data shows slightly better results when compared with the 
six-month data. This differs from previous studies reporting a so-called 
“honeymoon effect” with some loss of the positive outcome at medium-term 
follow-up (Blomqvist and Brandberg 2004, O'Blenes et al. 2006). Our patient 
population also showed significantly better values in some dimensions (usual 
activities and mental health) when compared to the age-standardised general 
population at two to five years’ follow-up. This is in contrast to previous studies 
(Blomqvist and Brandberg 2004, O'Blenes et al. 2006). Although our prospective 
follow-up study did not have a true control group, the above findings strongly 
suggest that the surgical result remains stable from short to medium-term (two to 
five years) follow-up. 
10.8 Future prospects 
The introduction of new outcome instruments hopefully provides better and 
adequate tools for assessing the condition caused by symptomatic hypertrophic 
breasts (Sigurdson et al. 2007a, Sigurdson et al. 2007b, Klassen et al. 2009, Pusic 
et al. 2009). Nevertheless, one of these questionnaires needs to be translated into 
Finnish, and this requires resources and sample sizes that can only be achieved by 
cooperation between several centres. However, in the present circumstances, when 
resources are continuously restricted, general outcome measures should 
complement these condition-specific instruments to allow us to compare the effects 
of different surgical treatments and medical conditions (Pusic et al. 2008, Cano et 
al. 2009, Pusic et al. 2010). Overall, a standardised, multi-centre data collection 
protocol would best serve both patients and plastic surgeons. This would provide 
data needed for updating the uniform criteria for access to non-emergency 
treatment of symptomatic breast hypertrophy. It will be challenging, maybe 
impossible, to set rigorous threshold levels for the medical necessity of reduction 
mammaplasty. However, adequate data collection will certainly provide valuable 
assistance for the clinical decisions. 
Although randomised controlled trials (RCTs) provide the most scientifically 
precise evidence, new RCTs with longer follow-up periods (up to one year, or even 
more) are probably not possible due to practical and ethical reasons. Instead, RCTs 
with larger patient populations could be valuable, especially with new outcome 
measures, as discussed above. Meanwhile, long-term (i.e., 10 years or more) 
follow-up studies are required to further substantiate the value of reduction 
mammaplasty. Also with these, a standardised data collection protocol is 
indispensable to achieve adequate and solid evidence. 
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11 CONCLUSIONS 
1. Reduction mammaplasty significantly improves quality of life and 
alleviates breast-associated symptoms and pain. Changes in the physical 
health were highly significant, whereas changes in the mental health were 
somewhat less pronounced. 
 
2. Reduction mammaplasty significantly alleviates depression and anxiety, 
and restores patients’ self-esteem. Preoperatively, half of the patients were 
depressed or anxious, or both. After reduction mammaplasty, four out of 
five showed no signs of depression or anxiety. 
 
3. Symptomatic breast hypertrophy causes an appreciable loss of health-
related quality of life when compared to the age-standardised general 
population. This health deficit is removed by reduction mammaplasty. 
 
4. The extent of the health deficit of symptomatic breast hypertrophy is 
similar to that caused by symptomatic major joint arthrosis. Preoperatively 
reduction mammaplasty patients had somewhat better quality of life than 
major joint replacement populations when results were standardised for age. 
 
5. The effects of reduction mammaplasty in terms of health-related quality of 
life are comparable to those of major joint replacement. The intervention 
effect is the same as in total hip joint replacement and more than two times 
that of total knee joint replacement. The intervention effect of reduction 
mammaplasty (in terms of quality of life) is two times the minimal clinical 
important difference. 
 
6. The outcome of reduction mammaplasty is affected more by preoperative 
psychosocial factors than by changes in breast dimensions. Especially 
preoperative anxiety was associated with outcome differences in the patient 
population. 
 
7. The effects of reduction mammaplasty remain clearly significant and stable 
at two to five years’ follow-up. This is demonstrated by fewer breast-
associated symptoms and  decreased psychological morbidity, as well as a 
better quality of life. A “honeymoon effect” was not detected, as the 
medium-term results were somewhat better than the short-term (6 months) 
results. 
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